SPECTRUM OF HISTOMORPHOLOGICAL PATTERNS OF UPPER

GASTROINTESTINAL TRACT ENDOSCOPIC BIOPSIES

By

DR. SNEHA JAWALKAR

Dissertation submitted to the

BLDE University, Bijapur, Karnataka



In partial fulfillment of the requirements for the award of the degree of

DOCTOR OF MEDICINE

IN

PATHOLOGY

Under the Guidance of

DR. SUREKHA U. ARAKERI_{MD}

Professor, Department of Pathology

BLDE UNIVERSITY'S, SHRI B.M. PATIL MEDICAL COLLEGE,

HOSPITAL & RESEARCH CENTRE, BIJAPUR, KARNATAKA.

2015

SHRI B.M.PATIL MEDICAL COLLEGE, HOSPITAL

& RESEARCH CENTRE, BIJAPUR

DECLARATION BY THE CANDIDATE

I hereby declare that this dissertation entitled "SPECTRUM OF HISTOMORPHOLOGICAL PATTERNS OF UPPER GASTROINTESTINAL TRACT ENDOSCOPIC BIOPSIES" is a bonafide and genuine research work carried out by me under the guidance of Dr. SUREKHA U. ARAKERI _{MD} Professor, Department of Pathology BLDEU Shri B.M.Patil Medical College, Hospital & RC, Bijapur, Karnataka.

Dr. SNEHA JAWALKAR

Place: Bijapur

Date:

SHRI B.M.PATIL MEDICAL COLLEGE, HOSPITAL

& RESEARCH CENTRE, BIJAPUR

CERTIFICATE BY THE GUIDE

This is to certify that the dissertation entitled "SPECTRUM OF HISTOMORPHOLOGICAL PATTERNS OF UPPER GASTROINTESTINAL TRACT ENDOSCOPIC BIOPSIES" is a bonafide research work done by Dr. SNEHA JAWALKAR in partial fulfillment of the requirements for the degree of Doctor of Medicine (Pathology)

Date:

Place: Bijapur

Dr. SUREKHA U. ARAKARI M.D

Professor

Department of Pathology,

BLDEU Shri B.M.Patil Medical College,

Hospital & RC, Bijapur, Karnataka

SHRI B.M.PATIL MEDICAL COLLEGE, HOSPITAL

& RESEARCH CENTRE, BIJAPUR

ENDORSEMENT BY HEAD OF DEPARTMENT

This is to certify that the dissertation entitled "SPECTRUM OF HISTOMORPHOLOGICAL PATTERNS OF UPPER GASTROINTESTINAL TRACT ENDOSCOPIC BIOPSIES" is a bonafide research work done by Dr. SNEHA JAWALKAR in partial fulfillment of the requirements for the degree of Doctor of Medicine (Pathology).

Date:

Place: Bijapur

Dr. B. R. YELIKAR

Professor and H.O.D,

Department of Pathology,

BLDEU Shri B.M.Patil Medical

College, Hospital & RC, Bijapur.

SHRI B.M.PATIL MEDICAL COLLEGE, HOSPITAL

& RESEARCH CENTRE, BIJAPUR

ENDORSEMENT BY PRINCIPAL / HEAD OF THE INSTITUTION

This is to certify that the dissertation entitled "SPECTRUM OF HISTOMORPHOLOGICAL PATTERNS OF UPPER GASTROINTESTINAL TRACT ENDOSCOPIC BIOPSIES" is a bonafide research work done by Dr. SNEHA JAWALKAR in partial fulfillment of the requirements for the degree of Doctor of Medicine (Pathology).

Date:

Place: Bijapur

Dr. M. S. BIRADAR

Principal,

Department of Pathology,

BLDEU Shri B.M.Patil

Medical College, Hospital & RC,

Bijapur

SHRI B.M.PATIL MEDICAL COLLEGE, HOSPITAL

& RESEARCH CENTRE, BIJAPUR

COPYRIGHT

DECLARATION BY THE CANDIDATE

I hereby declare that the BLDE University, Karnataka shall have the rights to preserve, use and disseminate this dissertation / thesis in print or electronic format for academic / research purpose.

Dr. SNEHA JAWALKAR

Date:

Place: Bijapur

© BLDE UNIVERSITY BIJAPUR, KARNATAKA

ACKNOWLEDGMENT

Words would not be sufficient to express my deepest gratitude and indebtedness to my honorable and esteemed teacher and guide **Dr. SUREKHA U. ARAKERI** _{MD} Professor, Department of Pathology, an outstanding and revered teacher for her avid interest, unremitting encouragement and invaluable guidance throughout the course of my study. Indeed it's an honor for getting the opportunity to express my most sincere gratitude to her.

I am equally grateful to **Dr. B.R.YELIKAR Professor and H.O.D, Department of Pathology** for his valuable suggestions given at all the steps of the study. Not only has he provided me with the analytical and conceptual tools to complete my study but he has also had a profound influence on both my personal growth and professional pursuits.

I am also extremely fortunate to have a caring, approachable and supportive department, who have advised and mentored me and made it conceivable for me to expedite this dissertation. I am thankful to **Dr. R.M.Potekar** Prof, **Dr. S.B.Hippargi** Prof, **Dr. Mahesh H. Karigoudar** Prof, **Dr. Girija Patil** Assoc Prof, **and Dr. Padmaja kulkarni** Assoc Prof, **Dr. Prakash Patil** Assoc Prof, **Dr. Vijayalaxmi S Patil** Asst. Prof, **Dr. Anita P Javalgi** Asst prof, **Dr. Mamatha K.** Asst prof and **Dr. Yashaswini S.P.** Asst Prof for their congenital supervision, assiduous concern and positive feedback at all steps of this work.

My sincere thanks to all my batchmates, seniors and juniors who have helped and encouraged me during my work. I am very grateful to all the non teaching staff of Department of Pathology, who has helped me during this work.

I am deeply indebted to my **parents**, **parents- in-law**, my husband **Dr.Rakesh** and all my **family members** for their help, constant encouragement and moral support that led me to successfully complete this dissertation work.

Last but not the least, my sincere gratitude to all my study subjects whose cooperation has contributed to this study. I would like to end with a motivational quote that graduate students should remind themselves of when research gets tough.

When you come to the end of your rope, tie a knot and hang on.

~Franklin D. Roosevelt

Dr. SNEHA JAWALKAR

Date:

Place: Bijapur

LIST OF ABBREVATIONS USED

GI	Gastrointestinal
UGIT	Upper gastrointestinal tract
UGE	Upper GI endoscopy
GERD	Gastroesophageal reflux disease
AIDS	Acquired immunodeficiency syndrome
I.V.	Intravenous
FNAC	Fine needle aspiration cytology
HPF	High power field
NSAIDS	Non steroidal antiinflamatory drugs
H. pylori	Helicobacter pylori
IHC	Immunohistochemistry
COPD	Chronic obstructive pulmonary disease
CRF	Chronic renal failure
NHL	Non-Hodgkin's lymphoma

ABSTRACT

BACKGROUND

Upper gastrointestinal (GI) endoscopy is a safe and well tolerated procedure. However endoscopy alone is insufficient to diagnose mucosal lesions in about 15-30% of cases. In these cases histopathological examination can be useful for the diagnosis of the upper GI lesions. Thus endoscopy in combination with biopsy acts as a useful adjunct for diagnosis of upper GI lesions and plays an important role in management of patients.

OBJECTIVE

To study the histomorphological patterns and frequencies of lesions in upper GI endoscopic biopsies.

MATERIALS

Upper GI endoscopic biopsies from July 2010 to July 2014 were studied. Endoscopic biopsies done for lesions in esophagus, stomach, first and second part of duodenum up to the opening of common bile duct were taken. The biopsy specimens were stained with Hematoxylin and Eosin. Other special stains like PAS, Giemsa and immunohistochemistry were done wherever required.

RESULTS

Total 196 upper GI biopsies were studied. 83(42.34%) were from esophagus, 47(23.97%) cases were from stomach, 49(25%) were from duodenum and 15(7.65%) were from gastroesophageal junction. One case was from esophagogastric anastomosis site in a case of post trans-hiatal esophagectomy(0.5%). Male to female

ratio was 2.26. Overall non-neoplastic lesions of upper GI biopsies were equal to neoplastic lesions. In esophagus most common lesion was squamous cell carcinoma. Among non neoplastic lesions, chronic esophagitis was more common. In stomach most commonly diagnosed lesion was adenocarcinoma followed by chronic gastritis.

In duodenum there were 41 cases of chronic duodenitis and there was one case of well differentiated adenocarcioma of periampullary region.

CONCLUSION

Endoscopic biopsy leads to an early diagnosis of various upper GI lesions. Hence the present study was done to determine the spectrum of upper GI lesions that help in early therapeutic decisions and management of the patients.

KEY WORDS: Endoscopic biopsy, histomorphology, upper gastrointestinal tract

TABLE OF CONTENTS

Sl. No.	Contents	Page No
1.	INTRODUCTION	1
2.	OBJECTIVES	3
3.	REVIEW OF LITERATURE	4
4.	MATERIALS AND METHODS	32
5.	RESULTS	33
6.	DISCUSSION	48
7.	CONCLUSION	55
8.	SUMMARY	56
9.	BIBLIOGRAPHY	57
10.	ANNEXURE	65

LIST OF TABLES

SL. NO.	TABLES	PAGE NO
1.	Distribution Of Cases According To Age And Sex	33
	Bar Diagram Showing Age & Sex Distribution Of Cases	34
2.	Distribution Of Cases According To Site.	35
	Pia Diagram Showing Site Wise Distribution Of Cases	36
3.	Distribution Of Neoplastic & Non-Neoplastic UGIT Lesions According To Site	37
4.	Distribution Of Non-Neoplastic Lesions Of Esophagus	38
5.	Distribution Of Neoplastic Lesions Of Esophagus	39
6.	Distribution Of Non-Neoplastic Lesions Of Stomach	40
7.	Distribution Of Neoplastic Lesions Of Stomach	41
8.	Distribution Of Lesions Of Gastroesophageal Junction	42
9.	Distribution Of Lesions Of Duodenum	42

Sl. No.	Figure	Page No.
1.	Photomicrograph of Barrett's esophagus (H&E stain 40x)	43
2.	Photomicrograph of Barrett's esophagus (H&E stain 400x)	43
3.	Photomicrograph of chronic gastritis with H. pylori infection (H&E stain 400x)	43
4.	Photomicrograph of H. pylori colonies in stomach (Giemsa stain 1000x)	43
5.	Photomicrograph of Inflammatory gastric polyp (H&E stain 100x)	44
6.	Photomicrograph of Inflammatory gastric polyp (H&E stain 400x)	44
7.	Photomicrograph of Hyperplastic gastric polyp (H&E stain 40x)	44
8.	Photomicrograph of Moderately differentiated adenocarcinoma of stomach (H&E stain 40x)	44
9.	Photomicrograph of Signet ring adenocarcinoma of stomach (H&E stain 400x)	45
10.	Photomicrograph of Well differentiated SCC of esophagus with Candidiasis (H&E stain 100x)	45
11.	Photomicrograph of Well differentiated SCC – esophagus with Candidal yeast forms and pseudohyphae (H&E stain 1000x)	45
12.	Photomicrograph of Candidal yeast forms and pseudohyphae (PAS stain 1000x)	45

13.	Photomicrograph of Moderately differentiated SCC of	46
	esophagus (H&E stain 100x)	
14.	Photomicrograph of Poorly differentiated SCC of esophagus	46
	(H&E stain 400x)	
15.	Photomicrograph of Celiac disease - duodenum	46
	(H&E stain 40x)	
16.	Photomicrograph of Well differentiated adenocarcinoma of	46
	duodenum -periampullary region (H&E stain 100x)	
17.	Photomicrograph of Poorly differentiated carcinoma	47
	(H&E stain 400x)	
18.	Photomicrograph of Poorly differentiated carcinoma showing	47
	focal positivity for CK7 (400x)	
19.	Photomicrograph of poorly differentiated carcinoma showing	47
	diffuse positivity for CK20 (40x)	
20.	Photomicrograph of MALToma of stomach (H&E stain 400x)	47

INTRODUCTION

Upper gastrointestinal (GI) endoscopy is a visual examination of the upper gastrointestinal tract (UGIT) using a lighted, flexible fibreoptic or video endoscope.¹ The use of flexible fibreoptic gastroscope is now a part of routine gastroenterological practice. Endoscopic examination is recommended with negative Barium X-rays, in patients with dyspeptic symptoms.² For most upper gastrointestinal lesions, the sensitivity and specificity of endoscopy is about 90% and nearly 100% respectively which is far higher than for barium radiography where sensitivity and specificity is about 50% & 90% respectively.³

The major advantages of endoscopy over contrast radiography in evaluation of diseases of the alimentary tract is direct visualization, resulting in a more accurate and sensitive evaluation of mucosal lesions. Other advantages are the ability to obtain biopsy specimens from superficial lesions and the ability to perform therapeutic interventions.³ Endoscopic appearance may be valuable in diagnosis of mucosal lesions but more accurate and detailed information results from histological examination of mucosal biopsy specimens.⁴

The indications of upper GI endoscopic (UGE) biopsy includes – evaluation of dyspepsia, dysphagia, GERD, Barrett oesophagus, dysplasia, peptic ulcer disease and its complications, gastric and oesophageal carcinomas.⁵

UGIT is a common site for tumors, especially malignant tumors. In India, according to the National Cancer Registry, esophageal and gastric cancers are the most common cancers found in men, while esophageal cancer ranks third among women.⁶

Endoscopy of gastrointestinal tract is a simple safe and well tolerated procedure. The visualization of proper site of mucosal lesion with biopsy leads to early detection of pathologic process and institution of early treatment.⁵

OBJECTIVES OF THE STUDY

To study the histomorphological patterns and frequencies of lesions in upper GI endoscopic biopsies.

REVIEW OF LITERATURE

Esophagogastroduodenoscopy is a procedure that visualizes the mucosal surfaces of the esophagus, stomach, and proximal duodenum and plays a major role in diagnostic and therapeutic modalities.⁷Endoscopic technology has evolved significantly in past 20 years with widespread availability of videoscopes.⁸

Adolf Kussmaul in 1868 at a meeting of the Freiburg Society of Naturalists with the good sense to use a professional sword-swallower for the demonstration – passed a hollow, rigid metal tube – the first gastroscope through the oesophagus into his subject's stomach. Illumination was provided by a Desormeaux lamp attached proximally, but visibility was poor. Leiter and Nitze developed a successful cystoscope and a crude gastroscope using the same technique. Leiter with von Mikulicz shifted the light to the distal end of the tube but retained the angulation of the shaft. The first semi flexible instrument which could be inserted into the stomach was developed by Schindler & Wolf in Germany in 1932.⁹ Hirschowitz , then embarked on the construction of a flexible gastroscope in1957.¹⁰

Japanese surgeons working in Tokyo were concerned about the high incidence of gastric cancer in their community. Hence they developed a gastrocamera in association with the Olympus Company in early 1950s for the purpose of early diagnosis of carcinoma of stomach. A community of physicians and surgeons, as well as a commercial organization in Japan was highly sympathetic to the use of new techniques in the investigation of gastro-intestinal disease. In 1962, Professor Tadayoshi Takemoto together with the Machida and with Olympus company, developed a new generation of fibre optic instruments for endoscopy that have swept the world.¹¹ Various methods such as narrow-band imaging, autofluorescence imaging, Raman spectroscopy, confocal endomicroscopy, endoscopic optical spectroscopy, and magnifying endoscopy have been developed and are under trial. These endoscopic detection methods have enabled endoscopists to collect real-time in vivo histological images or "virtual biopsies" of the GI mucosa during endoscopy.¹²

Indications of UGE biopsies include esophageal, gastric and duodenal ulcers, esophagitis, gastritis, duodenitis, polyps of upper gastrointestinal tract(UGIT), esophageal strictures, precancerous conditions - Barrett's esophagus, tumors of UGIT and in evaluation of malabsorption, iron deficiency anemia, celiac disease, AIDS enteropathy.^{1,7,13}

UGE is usually performed on an outpatient basis. The patient is advised not to eat, drink or smoke during the 8 hours before the procedure to ensure that the UGIT is clear. The throat is anesthetized by local anesthetic and I.V. sedation is given to relax the patient. The patient is made to lie on the back or side of the examination table. An endoscope is carefully fed down the esophagus into the stomach and duodenum. Tract is visualized and other instruments are passed through the endoscope to perform additional procedures like biopsy or removal of a polyp or a tumor.^{1,14} Tissue sampling has become an integral part of endoscopy procedure and is used to compliment endoscopic imaging. It is generally safe and effective .Various techniques include fine needle aspiration cytology, brush cytology, snare excision, and pinch forceps biopsy.¹⁵

Various biopsy forceps are available. Single-bite cold-biopsy forceps allow sampling of only a single specimen at a time. Double-bite forceps, are most commonly employed because they enhance directed lesion sampling via impalement of the tissue and stabilization of the forceps cups. Large-capacity or "jumbo" biopsy forceps sample a larger volume of tissue encompassing 2 to 3 times the surface area compared to standard forceps. Multiple bite sampling have been developed that can obtain up to 4 or more specimens on a single pass.¹⁵

Danesh BJZ *et al* ¹⁶ did a comparative study of weight, depth, and diagnostic adequacy of specimens obtained with 16 different biopsy forceps. They concluded that the precise shape, design, and make of the forceps used were not of practical importance. In their study they found that bigger, deeper, and more adequate specimens were obtained by using the standard sized forceps and by applying pressure at the time of biopsy.

A study done by Fantin AC *et al* 17 to assess and compare the diagnostic quality of biopsy specimens obtained with a conventional forceps and a multibite forceps found that the quality of biopsy specimens obtained with the multibite forceps is same as that of specimens taken with a conventional forceps. They concluded that the use of multibite forceps saves time. With multibite forceps 4 specimens can be obtained in 1 pass hence is useful in situations where a large number of specimens are needed or when the potential for transmission of infection is of concern.

A study done by Kim CG¹⁸ on tissue acquisition in gastric epithelial tumor prior to endoscopic resection showed that multiple deep biopsies can induce mucosal ulceration in early gastric cancer and they also found that ulcerative early gastric cancer was associated with piecemeal and incomplete resection. It is also associated with a higher risk of procedure-related complications such as bleeding and perforation.

Malhotra V *et al* ¹⁹ studied endoscopic techniques in the diagnosis of upper GI malignancies. They used brush biopsy, forceps biopsy, FNAC and suction cytology and concluded that forceps biopsy is the single most reliable and accepted technique when combined with any cytologic technique, the accuracy reaches 100%.

NORMAL HISTOLOGY OF UPPER GASTROINTESTINAL TRACT

Esophagus is composed of four layers namely mucosa, submucosa, muscularis propria and adventitia. Mucosa has has three components

- a) Non-keratinizing stratified squamous epithelium.
- b) Underlying lamina propria contains loose areolar connective tissue and scattered inflammatory cells. Finger like extensions of lamina propria, termed papillae extend into the epithelial layer usually up to one-third to one half of the thickness of the epithelial layer .In its distal portion, esophagus contains mucosal glands called as esophageal cardiac glands.
- c) Muscularis mucosae is absent in upper part, distinct in the lower part of the esophagus and is thickest near the esophagogastric junction. Submucosa consists of loose connective tissue, occasional lymphoid follicles and submucosal glands.²⁰ Muscularis propria consists of striated skeletal muscles fibres in upper third, striated and smooth muscle fibres in the middle third and exclusively smooth muscle in the lower third of the organ. It lacks a serosal layer except in the most distal portion.²¹

Esophago-gastric junction is formed where the esophagus joins the stomach. The non-keratinized stratified squamous epithelium of the esophagus abruptly changes to the simple columnar mucin secreting gastric epithelium of the cardiac region of the stomach. At this junction esophageal glands proper may be seen in submucosa. Lamina propria of the esophagus continues into the lamina propria of the stomach where it becomes filled with gastric and cardiac glands and with diffuse lymphatic tissue.²¹

Gastric wall consists of the mucosa, submucosa, muscularis propria and serosa. Mucosa consists of lining epithelium, lamina propria and muscularis mucosae.

Mucosa is lined by simple columnar surface epithelium extending into the gastric pits into which the tubular glands open. Lamina propria is made up of loose connective tissue and fills up the spaces between the gastric glands. Muscularis mucosae is made up of a thin layer of smooth muscle fibres and consists of inner circular and outer longitudinal layer.²² Submucosa consists of loose connective tissue with numerous elastic fibres. Muscularis externa is composed of three layers: outer longitudinal, inner circular and innermost oblique. Serosa consists of a thin outer layer of connective tissue and is covered by a simple squamous mesothelium of visceral peritoneum.^{21, 22}

All the gastric glands have two major components: foveola/crypts/pit and secretory portion known as adenomere. The foveolae represent the most important area for genesis of gastric carcinoma. Gastric glands vary in different anatomic regions of stomach. In Cardia of stomach, foveolae occupy the upper half. In the lower half of cardia, glands contain either pure mucus cells or a mixture of mucus and oxyntic cells. At fundus, the foveolae occupy only 1/4th of the thickness and glands of composite cell distribution which include chief cells, parietal cells (acid secreting), endocrine cells and mucus neck cells. In antral and pyloric glands, foveolae occupy the upper half. Glands contain both mucus secreting and endocrine cells. Cytoplasm of the pyloric cells can be bubbly, vacuolated, granular or glassy.^{21, 22}

Duodenum is composed of mucosa, sub mucosa, muscularis externa and serosa. Mucosa is lined by villi which are short and stubby (leaf like) in duodenum. Villous epithelium is composed of tall columnar absorptive cells (enterocytes) lined with microvilli (brush border) admixed with the lighter staining goblet cells. Between bases of villi are pit like crypts of Lieberkuhn, which contain stem cells that replenish and regenerate the epithelium.^{4, 22} Normal villous to crypt height ratio varies from 3:1

to 5:1.¹³ Lamina propria contains a loose connective tissue matrix containing lymphocytes, plasma cells and occasional eosinophils, macrophages, mast cells and neutrophils. Smooth muscle fibres from muscularis mucosae extend into core of individual villi and are responsible for their movements. Microvilli are cytoplasmic extensions that cover the apices of intestinal absorptive cells. Submucosa contains connective tissue and the submucosal Meissner's plexus along with numerous mucus secreting glands known as Brunner's glands. Muscularis externa is made up of an inner circular and outer longitudinal layer with the myenteric (Auerbach's) plexus, ganglion cells and perineural fibroblasts.^{21, 22}

NON-NEOPLASTIC LESIONS OF ESOPHAGUS

Reflux esophagitis/ GERD is esophagitis resulting from reflux of gastroduodenal contents into esophagus. Various conditions that causes mucosal injury are hiatus hernia, defective or weak lower esophageal sphincter (LES), impaired esophageal peristalsis with transient LES relaxation, delayed gastric emptying, decreased salivary gland secretions, increased gastric acid production and bile reflux.²³

In mild forms little or no abnormality may be seen. Mucosal erosions, ulcerations, intramural thickening, strictures or Barrett's esophagus were noted in more severe disease.²⁴ Many patients with clinical diagnosis of GERD have no abnormality on endoscopic examination and are labeled as endoscopic negative reflux GERD (ENRD). In such patients esophageal biopsy is useful in diagnosing the reflux disease.²⁵Microscopically, intraepithelial edema, necrosis, infiltration by neutrophils and eosinophils are seen in acute cases. Chronic cases have basal cell hyperplasia, elongation of papillae and intraepithelial eosinophils. More severe cases show ulceration, granulation and submucosal fibrosis.²⁶

A study done by Fiocca R *et al* 27 revealed that more number of biopsies and distal biopsies are the more informative and has higher diagnostic sensitivity in diagnosing microscopic esophagitis. They also found that the assessment of basal cell hyperplasia and papillae elongation requires well oriented biopsies.

Another study done by Brindley N *et al* 28 concluded that proper orientation of esophageal pinch biopsies improves histologic appraisal and increases the yield of esophagitis in children with GERD.

Kasap E *et al* 29 studied the correlation among standard endoscopy, narrow band imaging and histopathological findings in the diagnosis of non-erosive reflux disease and found that histopathological evaluation is most sensitive. Therefore taking a biopsy will remain useful.

Eosinophilic Esophagitis is a clinico-pathological condition characterized by esophageal and/or upper gastrointestinal symptoms (dysphagia,food impaction, GERD-like symptoms, etc); frequent association with a history of bronchial asthma; normal pH values; absent/poor response to high-dose proton pump inhibitor.²⁷ It occurs more frequently in young children with atopic symptoms such as eczema, asthama and food allergies.²⁶

Endoscopically, mucosal rings, furrows, granularity, exudates, and mucosal fragility is seen. In long standing cases, strictures can be seen.²⁶ Eosinophilic esophagitis show prominent intraepithelial eosinophilia and its diagnostic criteria is presence of more than or equal to 15 intraepithelial eosinophils/HPF, especially forming microabscesses in the superficial layers of the epithelium. Other disorders which may show similar clinical, histological, or endoscopic features such as GERD should be excluded.^{27, 30}

Most common forms of acute infectious esophagitis are viruses and fungi. Herpes esophagitis occurs primarily in immunosupressed patients. Endoscopically, herpetic ulcers are typically shallow, sharply punched out known as "volcano ulcers". Microscopic diagnostic criteria for herpes esophagitis includes the presence of Cowdry A intranuclear viral inclusion bodies, ground glass nuclei, nuclear moulding, margination of chromatin and multinucleate synctial squamous cells.^{22,26} Cytomegalovirus Esophagitis is also on the rise due to predilection for immunocompromised patients. Endoscopic picture shows discrete superficial ulcers in mid or distal esophagus. These coalesce to form giant ulcers. Histologically it shows cellular enlargement, prominent eosinophilic, intranuclear inclusions and occasional granular basophilic cytoplasmic inclusions.²⁴

Candida Esophagitis is most commonly caused by Candida Albicans and Candida Tropicalis. It occurs in patients with AIDS, diabetes, on antibiotic and immunosuppressant therapy. Endoscopically ,esophageal candidiasis typically appears as white plaques. Pseudohyphae and budding yeast forms can be demonstrated histologically in a background of active esophagitis.^{23,26} Primary bacterial esophagitis is very rare and if occurs, it is caused by the normal flora of mouth and upper respiratory tract i.e. Staphylococcus Aureus, Staphylococcus Epidermidis, Streptococcus pyogenes and Bacillus species. Histologically, bacterial infections produce a diffuse acute necrotizing process characterized by intense neutrophilic exudates, cellular necrosis and degeneration.²⁴

Chagas disease is a well known parasitic infection caused by the parasite Trypanosoma Cruzi. It is a chronic infection, subsequently progressing to megaesophagus.²⁴ Chemical Esophagitis is caused by a variety of irritants such as

11

alcohol, corrosive acids or alkalis. It may also be caused when medical pills lodge & dissolve in the esophagus i.e. Pill Esophagitis.²⁶

PRE NEOPLASTIC LESION

Barrett's esophagus(BE) is recognized endoscopically by columnar metaplasia of any length and histologically it shows specialized columnar epithelium lining a segment of distal esophagus above the level of the lower esophageal sphincter. It is seen most commonly in adults due to ulceration caused by GERD and subsequent reepithelialisation of esophageal squamous mucosa by columnar cells. These columnar cells differentiate from multipotential stem cells lying in the base of the mucosa. BE can also result from other noxious substances such as reflux of bile salts, lysophospholipids and pancreatic enzymes.²⁴ Metaplastic change from squamous to columnar epithelium goes through an intermediate stage known as multilayered epithelium which is characterized by basally located squamoid cells and superficial mucinous columnar cells.³¹ Endoscopically, patches of red, velvety mucosa extending upward from the GEJ are seen which are described as salmon colored mucosa. The columnar mucosa extends proximally circumferentially in a continuous sheet, in the form of finger like projections or as isolated islands. Depending on the length of the mucosa involved, BE is sub classified as long segment BE (>3 cm) and short segment BE (<3cm, difficult to detect on endoscopy).^{23, 24}

Microscopically, Barrett's esophagus is of three major types. a) Fundic type containing parietal cells and chief cells. b) Junctional type or cardiac type containing mucous secreting columnar cells of cardiac type. c) Distinctive type with specialized intestinal epithelium containing goblet cells. It is sometimes characterized by a villiform surface and crypts with a mixed population of columnar and goblet cells.²⁴ When these goblet cells are admixed with gastric type lining cells and is devoid of

absorptive and Paneth cells it is called as incomplete intestinal metaplasia.^{27,31} Distinctive type Barrett's esophagus are most susceptible to development of dysplasia and adenocarcinoma.³¹

In the study done by Khandwalla HE *et al* ³² they found that most (71%) patients were suspected to have columnar lined esophagus(CLE) on endoscopy. But these patients were negative for intestinal metaplasia on biopsy for 2 years following endoscopy. The findings support withholding BE diagnosis for individuals with suspected CLE.

Grading of dysplasia in Barrett's esophagus is classified in the following categories (a)Negative for dysplasia (b) Indefinite for dysplasia (c) Low grade dysplasia (d) High grade dysplasia (e) Intramucosal carcinoma.³¹

A study done by Sandick JWV *et al* ³³ revealed that adenocarcinoma in BE develops through stages of increasing severity of dysplasia and that endoscopic biopsy surveillance permits early detection of malignancy thereby reducing mortality from esophageal adenocarcinoma.

TUMORS OF ESOPHAGUS

Squamous Cell Carcinoma (SCC) is the commonest malignant tumour in the esophagus, affecting males more commonly. Its peak incidence is in the 5th to 6th decade. There is a marked geographic variation in incidence, the highest being in China, South Africa, and central Asia and low in Europe and North America.^{22, 34}

The risk factors for esophageal SCC include alcohol, tobacco use, poverty, caustics, esophageal injury, achalasia, tylosis, stricture, Plummer- Vinson syndrome, polycyclic hydrocarbons, nitrosamines and other mutagenic compounds and history of previous irradiation. Recent studies have suggested role for human papilloma viruses, especially types 16 and 18, in the pathogenesis of some esophageal cancers. The

molecular pathogenesis of SCC is not well defined but loss of tumor suppressor genes like P53 and P16/ INK4a have been implicated. The onset of esophageal SCC is insidious and ultimately produces dysphagia, odynophagia (pain on swallowing), and obstruction. The most common site is middle one third of esophagus (50%) followed by lower third.^{22, 23, 34}

Esophageal SCC appears as circumferential, often ulcerated growth with sharply demarcated margins. Early lesions often appear as small, grey white plaque like thickenings. Later it may be polypoidal or exophytic and protrude into the lumen. Histologically, SCC of the esophagus show a range of differentiation from abundantly keratinized, well-differentiated lesions containing prominent intercellular bridges to poorly differentiated, anaplastic, large or small cell tumors in which morphologic evidence of squamous differentiation can only be identified after prolonged searching. The variants include basaloid SCC, adenosquamous carcinoma (evidence of both SCC and malignant glandular counterpart), small cell carcinoma, sarcomatoid carcinoma, lymphoepithelioma like carcinoma and verrucous carcinoma.^{22, 23, 34}

Adenocarcinoma of esophagus typically arises in a background of BE and long standing GERD. The risk is greater in those with documented dysplasia and further increased by tobacco use, obesity and prior radiation therapy. It is more common in men than women and molecular studies suggest its association with mutation of P53 gene, loss of chromosome 17p allele and C-erb-B2 overexpression. Esophageal adenocarcinoma usually occurs in the distal third of the esophagus and may invade the adjacent gastric cardia.^{23, 35}

Endoscopically, they appear as flat or raised patches in an otherwise intact mucosa and may progress to large masses of 5 cm diameter. Microscopically, most examples are tubular or papillary adenocarcinomas of intestinal pattern and show variable differentiation. Adenocarcinoma of esophagus most commonly produce mucin and BE is frequently present adjacent to the tumor. Some tumors have the pattern of mucinous adenocarcinoma, with prominent extracellular mucus production, but the diffuse type of signet-ring carcinoma is very unusual. Non-Barrett's associated esophageal adenocarcinomas are extremely rare and are derived from heterotopic gastric mucosa located in the upper esophagus.^{34, 35}

NON-NEOPLASTIC LESIONS OF STOMACH

Acute gastritis is a transient mucosal inflammatory process that may be asymptomatic or cause variable degrees of epigastric pain, nausea and vomiting. It may result from the ingestion of alcohol, NSAIDs and other anti-inflammatory drugs which impair the mucosal protection mechanisms. Microscopically, the surface epithelium is intact, although scattered neutrophils may be present among the epithelial cells or within mucosal glands. An erosion is denoted by loss of superficial epithelium generating a mucosal defect limited to lamina propria, and is often accompanied by a pronounced neutrophilic infiltrate. Concurrent erosion and hemorrhage is termed as acute erosive hemorrhagic gastritis.²³

Chronic Gastritis has following two main features: i) Infiltration of lamina propria by inflammatory cells (Plasma cells & lymphocytes) ii) Atrophy of glandular epithelium. If the inflammatory infiltrate is limited to the foveolar region and not accompanied by glandular atrophy, it is termed as chronic superficial gastritis. If the inflammation is more extensive and accompanied by glandular atrophy, it is termed as chronic atrophy, it is termed as chronic distribution of mucosa with absence of inflammation, it is termed as gastric atrophy.^{22, 23} Two types of metaplastic change can occur in chronic gastritis, often in combination i.e. pyloric metaplasia of fundic mucosa and intestinal metaplasia. Endoscopically, well developed atrophic gastritis

and gastric atrophy produce a thin, smooth mucosa with undue prominence of submucosal vessels.²²

Chronic gastritis is divided into 2 types: 1) Type A or Autoimmune gastritis 2) Type B or Non-immune gastritis. Autoimmune gastritis is characterized by antibodies to parietal cells and intrinsic factor. There is reduced serum pepsinogen I concentration, antral endocrine cell hyperplasia, vitamin B12 deficiency and defective gastric acid secretion (achlorhydria) which affects fundus in a diffuse manner. Autoimmune gastritis is associated with loss of parietal cells resulting in megaloblastic anemia and hyperplasia of antral gastrin producing 'G' cells.²³ There is diffuse mucosal damage and atrophy of the oxyntic mucosa resulting in thinning and loss of rugal folds .Microscopically there is megaloblastic change in epithelial cells accompanied by a chronic inflammatory infiltrate and severe cases show intestinal metaplasia.^{22, 23}

Non-immune gastritis (type B) affects the antrum mainly and progresses proximally. The most common cause is infection with H.pylori before the discovery of which, other factors like psychologic stress, caffeine, alcohol and tobacco use were considered the primary causes.²²

H. pylori infection is the most common cause of chronic gastritis. The disease most often presents as a predominantly antral gastritis with high acid production which progresses to pan gastritis. The route of transmission of H. pylori is either oral –oral, faeco-oral, or environmental. H. pylori infection results in increased acid production and disruption of normal gastric and duodenal protective mechanisms.^{23, 36} H. pylori plays a significant role in the genesis of several gastric diseases, including acute gastritis, chronic gastritis, chronic active gastritis, follicular gastritis, intestinal metaplasia, hyperplastic polyps, gastric and duodenal ulcers, gastric adenocarcinoma and gastric lymphoma.^{24,37}

H. pylori are slender, curved spirals in the superficial mucous layer, where they tend to be attached to the epithelium at the site of intercellular junctions. In extreme cases, the organisms carpet the luminal surfaces of foveolar and mucous neck cells, and can even extend into the gastric pits. Occasionally, they can be present in the stomach as coccoid forms. These are solid, round, basophilic, dot like structures on routine histology.³⁶ Special stains to detect H. pylori are Giemsa , Warthin Starry, Gimenez, Toulidine Blue, Genta stains or by IHC.^{38,39}

Endoscopically, H. pylori–infected antral mucosa is usually erythematous and has a coarse or even nodular appearance.²³ Microscopically, inflammatory infiltrate mainly neutrophils accumulate within the lamina propria and some assume intraepithelial location and accumulate in the lumen of gastric pits to create pit abscesses. The superficial lamina propria includes large numbers of plasma cells, often in clusters or sheets, and increased numbers of lymphocytes and macrophages. Foveolar hyperplasia, features of degeneration, in severe cases - erosion, hemorrhage, and mucosal necrosis can be seen. Lymphoid aggregates, some with germinal centers, are frequently present and represent an induced form of mucosa-associated lymphoid tissue, or MALT, that has the potential to transform into lymphoma.^{22, 23, 37}

Cohen H and Laine N, ⁴⁰ in their study on endoscopic methods for diagnosis of H. pylori states that when diagnosis of H. pylori is desired, two antral biopsies from non adjacent sites should be taken for rapid urease testing. Two or more additional biopsies should be stored for histological evaluation. They stated that although histological assessment is not free of pitfalls, it is the gold standard.

17

In the study done by Akanda MR and Rahman AN,⁴¹ the sensitivity of endoscopic biopsy smear examination, rapid urease test, Haematoxylin & Eosin stain and modified Giemsa stained sections are 86.2%, 96.6%, 77.6% and 86.4% and the specificity is 100%, 97.7%, 97.7% and 97.6% respectively.

A study done by Ahsan K *et al* 42 concluded that the diagnostic accuracy of crush smear cytology for detection of Helicobacter pylori in gastric biopsy material is comparable to histopathology and the technique is very simple, less expensive and less time consuming.

A study done by Ahluwalia C *et al* 43 revealed that use of brush cytology than conventional biopsy for detection of H. Pylori is recommended as it is rapid, simple and easy to perform with a high degree of sensitivity and specificity.

Another study by Seth AK *et al* ⁴⁴ reveals that biopsy of gastric antrum should always be combined with biopsy from the gastric corpus especially in endoscopic gastritis of corpus for diagnosing H. Pylori in patients with peptic ulcer on acid suppression therapy.

Other rare types of gastritis include suppurative gastritis, emphysematous gastritis, hemorrhagic gastritis, collagenous gastritis ,lymphocytic gastritis, allergic gastro-enteritis, diffuse eosinophilic gastritis, granulomatous gastritis , syphilis , malakoplakia, cytomegalovirus infection, herpes virus infection, candida infection, cryptococcosis, , and graft versus host diseases.^{24,37} Metaplasias in gastritis are of four major types - pyloric metaplasia, intestinal metaplasia, ciliated cell metaplasia, pancreatic(acinar) metaplasia.^{24,45}

Peptic Ulcer Disease (PUD) is most often associated with H. Pylori induced hyperchlorhydria and chronic gastritis. It's most common site is gastric antrum and 1st portion of duodenum. Imbalance of mucosal defenses and damaging forces are responsible for peptic ulcer disease. The primary underlying causes are H. pylori and NSAIDS which cause hypergastrinemia resulting in PUD. Duodenal ulcers are common with alcoholic cirrhosis, COPD, CRF, hyperparathyroidism.^{22, 23}

Endoscopically, lesions less than 0.3cm in diameter are shallow while those over 0.6 cm are likely to be deeper ulcers. The ulcer is usually round to oval with sharply punched out defect with overlying of mucosal margins. Hemorrhage and fibrin deposits are often seen in the gastric serosa. The base is smooth and clean and in active ulcers, neutrophilic infiltration along with granulation tissue is seen.^{22, 23}

Gastric Polyps

Gastric polyps may develop as a result of epithelial or stromal cell hyperplasia, inflammation, ectopia or neoplasia.²³

Peutz – Jeghers polyps most commonly present in childhood, are 1-3cm in size with a coarsely lobulated surface and a short, broad stalk. The most useful diagnostic feature is the presence of a core of family arborizing branches of smooth muscle from muscularis mucosa which is covered by abundant but disorganised gastric mucosa. Juvenile polyps, sometimes called retention polyps are round, smooth surfaced lesions of 1-2 cm diameter consisting principally of lamina propria rarely confined to the stomach.³⁶

Hyperplastic Polyps are common in both children & adults typically occurring at the junction of pyloric and corpus mucosa, generally varying from 0.5-2.5 cm in diameter having a coarsely lobulated surface. Smaller polyps are sessile while the larger ones have a stalk. The presumed histogenesis is an exaggerated regenerative response to mucosal damage. The histology is variable but basically they consist of elongated, distorted and branched gastric pits with inflamed & edematous lamina propria. The pit lining cells are frequently hypertrophic and nuclei are typically bland.³⁶

Fundic gland polyps has been described in two clinical situations –sporadic following widespread use of PPIs and syndromic in familial adenomatous polyposis(FAP) where hundreds of gastric polyps are present. They are present exclusively in the body or fundus and are multiple in clusters. Endoscopically they are soft, sessile, smooth, translucent and appear as minute mucosal lumps 1-7 mm in diameter. Microscopically, fundic gland polyps consist of proliferation of oxyntic mucosa with cystically dilated fundic glands, lined by an attenuated layer of chief cells, parietal cells and mucus neck cells.³⁷

Inflammatory fibroid polyp are polyps whose pathogenesis is unknown but is widely assumed to be related to minor trauma and a myofibroblastic origin has been proposed. It involves the antrum. Grossly, it is sessile. Microscopically, it is centered in the submucosa characterized by vascular & fibroblastic proliferation & inflammatory cells especially eosinophilic infiltration.^{36,37} Cronkhite-Canada syndrome is extremely rare condition and is characterized by diffuse GI polyposis, alopecia, hyperpigmentation, and dystrophic changes in fingernails and toe nails. Endoscopically, the polyps are sessile. Histologically, they consisting of hyperplastic, edematous mucosa with epithelial cysts. They resemble hyperplastic polyps and juvenile polyps.³⁶

Adenomas comprise 7-10% of all gastric polyps and are sessile or pedunculated and grow in a tubulovillous or a pure villous pattern.³⁶ They occur throughout stomach with antrum being the most common site. They range from few milimeters to several centimetres. Histologically, they are of two types: showing intestinal differentiation and gastric differentiation. The gastric adenomatous polyps

are composed of gastric foveolar cells. Intestinal type defined by presence of goblet cells or paneth cells.³⁷ GI adenomas have epithelial dysplasia that can be classified as low or high grade. Both grades may include enlargement, elongation, and hyperchromasia of epithelial cell nuclei, epithelial crowding, and pseudostratification. High-grade dysplasia is characterized by more severe cytologic atypia and irregular architecture, including glandular budding and gland-within-gland, or cribriform, structures.²³

A study done by Carmack *et al* ⁴⁶ on gastric polyps revealed that a variety of gastric lesions might present as a polyp, and the need to obtain a biopsy specimen from the gastric mucosa adjacent to a lesion is critical.

TUMORS OF STOMACH

Gastric adenocarcinoma is the most common malignancy of the stomach seen in low socio-economic groups and in individuals with multifocal mucosal atrophy and intestinal metaplasia. Few studies also show an association with H. pylori infection. Gastric cancer incidence varies markedly with geography, being highest in Japan, Chile, Costa Rica, and Eastern Europe. All gastric carcinomas arise from the generative or basal cells of the foveolae. Loss of ECadherin function seems to be the key step in development of diffuse cancer whereas mutations in Catenin, microsatellite instability and accumulation of p53 are associated with intestinal type gastric carcinoma. Any condition causing hypochlorhydria decreases the gastric pH favouring bacterial growth which reduces nitrates to N-Nitroso compounds which are carcinogenic. Patients of Menetrier's disease, gastric polyp, gastric peptic ulcer, gastric stump, irradiation and chemotherapy are at increased risk for developing carcinoma.^{22, 23, 34}
The most common site is anterior wall then the posterior wall and lesser curvature more than greater curvature. Endoscopically, it may appear polypoid, fungating, ulcerated or diffusely infiltrating so-called linitis plastica types, or may show a combination of these.³⁴ With adequate biopsy material, the diagnostic accuracy of gastric biopsies for cancer is 83%.³⁶

Microscopically, the World Health Organization classification subdivides gastric carcinoma into five subtypes: papillary, tubular, mucinous, signet-ring cell adenocarcinomas and undifferentiated carcinoma, in which no definite glandular structures or any other specific differentiation is present.³⁴ Adenocarcinomas may also be graded as well, moderately or poorly differentiated. Papillary adenocarcinoma is characterized by numerous papillary processes with fibrovascular cores. Tubular adenocarcinoma is composed predominantly of neoplastic tubules often showing irregular branching and anastomosis. Mucinous adenocarcinoma (colloid or mucoid carcinoma) is characterized by conspicuous amounts of extracellular mucin (more than 50% of the tumor). Signet-ring cell carcinoma consists predominantly of single cells or small clusters of cell containing intracytoplasmic mucous vacuoles and accounting for more than 50% of the tumor.³⁴

The histologic classification of Lauren divides gastric adenocarcinoma into two main types – intestinal and diffuse.³⁴

- a) Intestinal type adenocarcinoma arises from metaplastic epithelium with glandular formations. The cells are columnar & mucin secreting, the increased secretion of which may cause formation of mucin- lakes which, when long standing may lead to metastatic calcification & ossification.
- b) Diffuse type adenocarcinoma is classically known as Linitis Plastica or signet ring carcinoma. It commonly involves the pre-pyloric area and associated with

submucosal fibrosis with or without ulceration. The tumor is composed of dyscohesive cells, having large mucin vacuoles that expand the cytoplasm and push the nucleus to the periphery forming the signet ring cell. The secretory product of most adenocarcinomas is positive with Meyer's Mucicarmine, Alcian blue, Colloidal iron and shows IHC positivity for MUC1, MUC5AC, and MUC2.²²

The other microscopic variables include adenocarcinoma with neuroendocrine differentiation, adenosquamous carcinoma, mucinous carcinoma, hepatoid adenocarcinoma, oncocytic (parietal gland) carcinoma, lymphoepithelioma like carcinoma, sarcomatoid carcinoma, adenoma with rhabdoid features and gastric carcinoma with osteoclast – like giant cells.²²

Early Gastric Cancer is defined as carcinoma confined to the mucosa or to the mucosa & submucosa, most commonly seen in the distal third of the stomach. Most cases are of the intestinal type.²² Endoscopically, they are classified as superficial protruding or non-protruding lesions, protruding pedunculated or protruding sessile. Non-protruding and non-excavated lesions include slightly elevated, completely flat, slightly depressed, elevated & depressed types. Excavated lesions may be further divided into ulcer and excavated & depressed type.⁴⁷

Well-differentiated neuro-endocrine tumors (WDNETS) are mainly composed of serotonin containing argentaffin cells. There are 2 types of gastric WDNETscomposed of G cells (Gastrinoma) and Enterochomaffin like (ECL) cells. Endoscopically, they tend to be small, sharply outlined and covered by flattened mucosa, usually intramural/submucosal polypoidal lesions. Microscopically, the predominant pattern of arrangement is microglandular, with regular nuclei and normochromatic, scanty mitosis with absent necrosis and florid vascularisation and exceptionally clear cytoplasm. Immunohistochemically, they are positive for chromogrannin, synptophysin and keratin.^{22, 34}

Gastrointestinal Stromal Tumor (GIST) is the most common mesenchymal tumor of the abdomen with more than 50% cases occurring in stomach. It is seen in older age group (60yrs and above). They may occur as part of Carnoy's triad: GIST, Pulmonary chondromas, extra- adrenal pargangliomas. All GISTS have gain – of – function mutations of the gene encoding tyrosine kinase CKit (receptor for stem cell factor). The cell of origin is a common stem cell i.e. interstitial cell of Cajal, located in muscularis propria which serves as pacemaker cells for gut peristalsis.²³ GIST is divided into 4 major categories:

- A) Tumors showing differentiation towards smooth muscle cells (Actin +, Desmin+,Calponin+).
- B) Tumors showing apparent differentiation toward neural elements (NSE+, Leu -7+, S-100+).
- C) Tumors showing differentiation towards smooth muscle and neural elements.
- D) Tumors lacking differentiation to either cell type (CD34+).²²

The smooth muscle differentiation is identified by spindle tumor cells with acidophilic fibrillary cytoplasm and cytoplasmic vacuoles at both ends of nucleus. An epithelioid appearance may be present. The neural differentiation is identified by spindle cells growing in fascicles, palisades & whorls and presence of skenoid fibres i.e, deposition of extracellular, amorphous collagen. The defining criteria for diagnosis is CD117 positivity (membrane component).^{22, 34}

Malignant lymphoma of the stomach accounts for 10% of gastric malignancies. It may be primary, or secondary to systemic lymphoma. Features favouring a primary tumor are concentration of the major tumor bulk within the stomach and /or the regional lymph nodes without involvement of superficial or mediastinal lymph nodes, liver, spleen, bone marrow or peripheral blood. It is of the MALT type (mucosa associated lymphoid tissue present in lamina propria) and virtually all tumors arise in the background of chronic Helicobacter associated gastritis.^{34, 36}

It is divided into 2 large categories:

- a) Low grade lymphomas (MALT type) are seen in patients over 50yrs in distal half of stomach. Endoscopically, giant convolutions mimicking hypertrophic gastritis or gastric polyps are present. Microscopically, transmural involvement is seen with focal or extensive plasmacytoid differentiation and dutcher bodies may be present. An important diagnostic sign is the infiltration of the glandular epithelium by the lymphocytes called as lymphoepithelial lesions.
- b) Intermediate / high grade lymphomas endoscopically appears as a large lobulated (polypoid) mass with superficial /deep ulceration. Histologically, it is composed of cells resembling large non-cleaved cells (centroblasts) but with a slightly more abundant cytoplasm, plasmablastic or immunoblastic appearance. MALT lymphoma cells express B-cell antigens CD20, and CD79a, but not CD5, CD10 or CD23. Endoscopic and histological examination combined with flow cytometry has significance for the diagnosis of GI B- cell lymphoma as a screening tool.²²

NON-NEOPLASTIC LESIONS OF THE DUODENUM

Chronic duodenitis induced by H. pylori endoscopically shows duodenal gastric metaplasia (DGM) . H. pylori in duodenum may produce chronic gastritis, duodenal ulcer, duodenal bulb deformity and scarring. DGM and H. pylori are usually found in proximal duodenum and H. pylori colonizes the duodenal mucosa only in areas of gastric metaplasia.^{13, 22}

A study done by Chu KM *et al* ⁴⁸ revealed that 90% of the patients with duodenal ulcer are infected by H pylori.

Eosinophilic Duodenitis is diagnosed by presence of gastrointestinal symptoms, biopsy specimens showing eosinophilic infiltration of one or more areas of duodenum and no evidence of parasitic, intestinal or extraintestinal disease. Duodenum may be affected along with other segments of the intestine.¹³

Gonul CD *et al*⁴⁹ studied the clinical significance and histopathologic features of duodenal nodularity in children. Their study revealed that the most demonstrative histomorphology in duodenal mucosa is increased lymphocyte and eosinophil infiltration in children with duodenal nodularity.

Gluten-sensitive enteropathy (GSE) also known as celiac disease or celiac sprue, is seen due to ingestion of gluten containing cereals, such as wheat, rye or barley in genetically predisposed individuals. Endoscopically , the duodenal folds appear to be reduced or absent. Microscopically, the villi are atrophic/ absent; there is crypt hyperplasia and intraepithelial lymphocytosis. There is increase in the number of lymphocytes, plasma cells in lamina propria & accumulation of large fat globules in the surface epithelium.^{22, 23}The combination of histology and serology is most specific for diagnosis of celiac disease. However a single duodenal biopsy, followed by a favourable response to the gluten free diet, is sufficient to confirm the

diagnosis.⁵⁰The most sensitive tests are the presence of IgA antibodies to tissue transglutaminase or IgA or IgG antibodies to deamidated gliadin. Anti-endomysial antibodies are highly specific but less sensitive.²³

Marsh Classification for histological grading of celiac disease consists of a four-stage grading system with 40 intraepithelial lymphocytes (IEL) per 100 epithelial cells as the normal upper limit: Type I: infiltrative lesion, characterized by intraepithelial lymphocytosis and a normal villous architecture of the duodenal mucosa. Type II: hyperplastic lesion, characterized by intraepithelial lymphocytosis and crypt hyperplasia, with a normal villous architecture. Type III: destructive lesion, characterised by intraepithelial lymphocytosis, crypt hyperplasia and villous atrophy. Type IV: hypoplastic lesion, characterised by a normal IEL count, normal crypt length and villous atrophy.⁵¹

Oberhuber *et al* 52 modified this classification by splitting the type III lesions in three substages: mild villous atrophy, marked villous atrophy and completely flat mucosa.

A study done by Prasad KK *et al* 53 revealed that due to different concentrations of toxic gliadin fragment during its passage to different part of duodenal mucosa, a high frequency of histological lesion variability of the duodenal mucosa is seen in Indian children with celiac disease. Therefore, during upper gastrointestinal endoscopy at least 4 duodenal biopsies (2 in the distal duodenum and 2 in the duodenal bulb) should be obtained to avoid the risk of underdiagnosis or misdiagnosis.

A study done by Mee AS *et al* 54 reveals that the most reliable method for diagnosing or excluding villous atrophy is endoscopic forceps biopsy of the

27

descending duodenum, provided that at least four specimens are obtained with standard size forceps.

Mouzan MIE *et al* 55 stated that endoscopic duodenal biopsy in children is adequate not only for the diagnosis of villous atrophy but also for detection of other gastroenteropathies.

Refractory sprue is defined as symptomatic, severe small intestinal villous atrophy mimicking GSE, not responding to at least 6 months of gluten free diet. Architectural changes in duodenal biopsy specimen range from partial to total (grade IV) villous atrophy with a diffuse and dense mononuclear infiltrate mainly plasma cells in the lamina propria and a massive increase in IEL count. ¹³

Cow's milk protein-sensitive Enteropathy (CMSE) may affect school-aged children and in young adults with unexplained GI symptoms. The duodenal villous changes are not seen, however, duodenal IEL count expressing T-cell intracellular antigen I, perforin and granzyme A is increased. Lymphonodular hyperplasia, without villous atrophy found in bulb of duodenum, characterizes CMSE endoscopically.¹³

Whipple's disease is a multisystemic disorder caused by bacterium Tropheryma whipplei. It is an intracellular bacterium. Thickening of duodenal villi is seen with the lamina propria packed with foamy macrophages with numerous PAS positive, diastate resistant intra-cytoplasmic granules. HIV Enteropathy may be defined as atrophy with epithelial hypoproliferation and dysmaturation of enterocytes, which in turn impairs small bowel absorption. The histological features include normal villous architecture to partial villous atrophy, marked depletion in mucosal CD4 T lymphocytes, an increase in CD8 lymphocyte count and increased crypt depth with normal mitoses per crypt. Also, GI opportunistic infections like microsporidiosis, cyclosporidiosis, isosporidiosis, cryptosporidiosis, mycobacteriosis, cryptococcosis, visceral leishmaniasis, etc. may be detected on endoscopic biopsy.¹³

TUMORS OF DUODENUM

Brunner's gland adenoma (Polypoid Hamartoma / Brunneroma) is most commonly located in the posterior wall of the duodenum at the junction between the first and second portions. It can be associated with duodenitis and erosions. It is characterized by a nodular proliferation of histologically normal Brunner's glands accompanied by ducts and scattered stromal elements. It may be accompanied by ciliated cysts and adipose tissue and can be focal, multifocal or diffuse.²²

Adenomas of the small intestine are uncommon. The periampullary region is a site of predilection. Multiple duodenal adenomas are a frequent complication of FAP but usually remain small. Morphologically they are sessile or pedunculated. Adenomas are composed of tubular and/or villous structures lined by dysplastic epithelium. Mitotic activity is not limited to the basal zone and is often accentuated within the upper crypt and surface epithelium. The crypts show architectural irregularities. Based on their architecture, they are classified as tubular, tubulo-villous and villous.^{22, 56}

Primary duodenal adenocarcinoma is a rare tumor with a poorly defined natural history and prognostic factors. It represents 0.3-1% of all GI tumors and 25-35% of malignant tumors of the GI.⁵⁷ Although most cases are sporadic, associations with FAP, crohn's disease, peutz-jegher's syndrome and neurofibromatosis I have been reported.⁵⁸

Duodenal carcinoma tends to have a papillary configuration and is hence amenable to brush cytologic diagnosis.²² The periampullary region of the duodenum is the most common site and patients present with painless jaundice and bleeding. They present as polypoid or ulcerated tumors often with a co-existing adenoma. Microscopically, most adenocarcinomas are well or moderately differentiated. Mucinous adenocarcinomas occur, but signet-ring cell carcinoma is rare and should be distinguished carefully from secondary spread from other sites, notably the stomach. Ampullary adenocarcinomas are mainly intestinal in type.⁵⁶

Duodenal endocrine tumors or primary duodenal carcinoids account for only 2.6% of carcinoid tumors in the US.⁵⁹ Endoscopically, duodenal endocrine tumors appear as smooth, round elevations, usually measuring 5-20 mm in diameter. Microscopically, they rarely have the features of a classic carcinoid tumor, many cases containing either G or D cells, but both have a well developed glandular component and in addition, the D cell tumors have numerous psammoma bodies usually within the glandular lumina.²²

Stromal tumors have been thought to arise from an uncommitted mesenchymal cell. New category i.e gastrointestinal autonomic nerve tumors (GANTs) appear to occur in the small intestine. They can be classified as either non-myogenic stromal tumors(activating c-kit mutations positive) or true smooth muscle tumors{ c-kit (CDII7) immuno-negativity and positivity for smooth muscle actin and desmin}. Macroscopically, tumors may grow into the lumen, outwards through the serosa, or in both directions producing a dumbbell growth. GANTs typically extend into the mesentery or retroperitoneum. Microscopically, cells may be spindled or epithelioid. GANTs are described as having a well-developed microvasculature that is prone to focal hemorrhage. Nuclear palisading giving a plexiform appearance with a marked inflammatory component may favor a diagnosis of GANT.⁵⁶

Primary lymphomas are uncommon but account for about 30% of small bowel malignancies. They are divided into B-cell and T-cell malignancies. B-cell

malignancies include MALToma, immunoproliferative small intestinal disease, Mediterranean lymphoma, Burkitt's lymphoma, mantle cell lymphoma, follicular lymphoma, plasmacytoma. T- cell lymphomas include lymphoma arising in celiac disease and T-cell lymphoma with eosinophilia.⁵⁶

MATERIALS AND METHODS

Source of data:

The present study included endoscopic biopsies of upper gastrointestinal tract received in the Department of Pathology, B.L.D.E. University's Shri B.M.Patil Medical College, Hospital & Research Centre, Bijapur.

Study period - Two years retrospective and two years prospective endoscopic biopsies received from July 2010 to July 2014 were included in the study.

Inclusion criteria:

Endoscopic biopsies done for lesions in esophagus, stomach, first part and second part up to opening of common bile duct in the duodenum were included.

Exclusion criteria:

Biopsies done for lesions of the oropharynx were excluded.

Method of Collection of data:

The biopsy specimens received were fixed in 10% buffered formalin followed by tissue processing and embedding in paraffin. Then sections of 3-5 micron thickness were prepared and stained with routine Haematoxylin and Eosin. Other special stains like Periodic Acid Schiff (PAS), Giemsa stain and IHC were performed wherever necessary.

Sample size:

In any statistical analysis, in case of non- availability of prevalence or incidence rate, a sample size of 30 or more are generally considered adequate with the assumption that the sampling distribution of mean is approximately normal.

Hence a total of 196 UGE biopsies were studied.

Statistical methods:

- Diagrammatic presentation
- Percentage of various histomorphological patterns.

RESULTS

A total of 196 UGIT biopsies were obtained and studied over a period of four years from June 2010 to July 2014. Out of 196 cases, 6 cases were inadequate for opinion, 4 were esophageal biopsies and 2 were duodenal biopsies.

AGE IN YEARS	MALE	FEMALE	TOTAL
1-10	02	00	02
11-20	05	01	06
21-30	16	06	22
31-40	14	03	17
41-50	26	15	41
51-60	25	12	37
61-70	30	14	44
71-80	16	08	24
81-90	02	01	03
TOTAL	136(69.38%)	60(30.62%)	196

TABLE NO.1: DISTRIBUTION OF CASES ACCORDING TO AGE AND SEX

UGE biopsies were obtained from patients of 4 years to 87 years of age. Majority of cases were between 40 to 70 years of age. Out of 196 cases 136 (69.38%) were from males and 60(30.61%) were from females with a male to female ratio of 2.26:1.



DISTRIBUTION OF CASES ACCORDING TO AGE AND SEX

Sl	SITE	NO. OF	PERCENTAGE%
No.		CASES	
1.	Esophagus	83	42.34%
	Upper	05	6.02%
	Middle	47	56.62%
	Lower	31	37.34%
2.	Stomach	48	24.48%
	Fundus	07	14.58%
	Corpus	03	6.25%
	Antrum	02	4.16%
	Pre pyloric	18	37.5%
	Pyloric	18	37.5%
3.	Duodenum	49	25%
4.	Gastroesophageal junction	15	7.65%
5.	Esophagogastric anastomosis site	01	0.5%
	TOTAL	196	100%

TABLE NO.2: DISTRIBUTION OF CASES ACCORDING TO SITE



Out of 196 cases, 83(42.34%) were from esophagus, 47(23.97%) cases were from stomach, 49(25%) were from duodenum and 15(7.65%) were from gastroesophageal junction. One case was from esophagogastric anastomosis site in a case of post trans-hiatal esophagectomy accounting for 0.5% .In esophagus, mid esophagus was the most common site of biopsy. In stomach, pylorus and pre-pyloric region were the most common sites.

TABLE NO. 3: DISTRIBUTION OF NEOPLASTIC & NON-NEOPLASTIC

SITE	NON-	NEOPLASTIC	INADEQUATE	TOTAL
	NEOPLASTIC			
Esophagus	22(26.50%)	57(68.67%)	04(4.81%)	83
Stomach	23(48.93%)	25(52.08%)	00	48
Duodenum	46(93.87%)	01(2.04%)	02(4.08%)	49
Gastroesophageal junction	04(26.66%)	11(73.33%)	00	15
Esophagogastric anastomosis site	00	01(1.06%)	00	01
Total	95(48.46%)	95(48.46%)	6(3.09%)	196

UGIT LESIONS ACCORDING TO SITE

In esophagus, neoplastic lesions (68.67%) were more common than non neoplastic lesions(26.5%). In stomach, neoplastic lesions were 52.08% and non-neoplastic lesions were 48.93%. In duodenum, non-neoplastic lesions (93.87%) were far more common than neoplastic lesion (2.04%). In GEJ, 26.66% cases were non-neoplastic and 73.33% cases were neoplastic. The biopsy from esophagogastric anastomosis site showed moderately differentiated SCC which recurred following transhiatal esophagectomy. 6 cases (4 cases from esophagus and 2cases from duodenum) were inadequate to opine as there was only scant tissue or only epithelium without subepithelial tissue or only fibroconnective tissue.

TABLE NO. 4: DISTRIBUTION OF NON-NEOPLASTIC LESIONS OF

Sl. No	HISTOMORPHOLOGICAL PATTERN	NO. OF CASES
1.	Chronic non-specific esophagitis	11(50%)
2.	Hyperplastic polyp	01(4.54%)
3.	Ciliated metaplasia	01(4.54%)
4.	Ulcer with granulation tissue	01(4.54%)
5.	Barrett's esophagus	04(18.18%)
6.	Chronic esophagitis with mild dysplasia	01(4.54%)
7.	Chronic non specific esophagitis with moderate dysplasia	01(4.54%)
8.	Mild dysplasia	02(9.09%)
	Total	22

ESOPHAGUS

Amongst the non neoplastic lesions of esophagus, chronic esophagitis was most common lesion accounting to 13/22 cases (59.09%). Out of 4 cases of dysplasia, 2 cases showed features of esophagitis. 4 cases were diagnosed as Barrett's esophagus. There was one case each of hyperplastic polyp, ciliated metaplasia and ulcer with granulation tissue.

TABLE No. 5: DISTRIBUTION OF NEOPLASTIC LESIONS OF

Sl. No	HISTOMORPHOLOGICAL PATTERN	NUMBER OF CASES
1.	Squamous cell carcinoma(SCC)	51(89.47%)
	Well differentiated	15(29.41%)
	Moderately differentiated	29(56.86%)
	Poorly differentiated	07(13.72%)
2.	Adenocarcinoma	02(3.5%)
	Well differentiated	01(50%)
	Moderately differentiated	01(50%)
3.	Poorly differentiated carcinoma	03(5.26%)
4.	Highly suspicious for malignancy	01(1.75%)
	TOTAL	57

ESOPHAGUS

Amongst the neoplastic lesions of esophagus, moderately differentiated squamous cell carcinoma was most commonly diagnosed lesion. One case of well differentiated SCC was associated with candidiasis. There were 2 cases of adenocarcinoma, both were from lower segment of esophagus. Out of 3 cases of poorly differentiated carcinoma, for 2 cases differential diagnosis of small cell carcinoma was suggested based on histomorphology. In one case of esophageal biopsy, diagnosis of suspicious for malignancy was suggested for which follow up was not available.

TABLE No. 6: DISTRIBUTION OF NON-NEOPLASTIC LESIONS OF

Sl. No	HISTOMORPHOLOGICAL PATTERN	NUMBER OF CASES
1.	Chronic non-specific gastritis	15(65.21%)
2.	H.pylori gastritis	02(8.69%)
3.	Chronic gastritis with intestinal metaplasia	02(8.69%)
4.	Ulcer with suppurative necrosis	01(4.34%)
5.	Candidal infection	01(4.34%)
6.	Inflammatory polyp	01(4.34%)
7.	Hyperplastic polyp	01(4.34%)
	Total	23

STOMACH

The most commonly diagnosed lesion amongst non-neoplastic lesions of stomach was gastritis. 2 cases were of H. pylori gastritis and in 2 cases of chronic non-specific gastritis, intestinal metaplasia was noted.

Sl.No.	HISTOMORPHOLOGICAL PATTERN	NO. OF CASES
1.	Adenomatous polyp	01(4%)
2.	Adenocarcinoma	17(68%)
	Well differentiated	04(23.52%)
	Moderately differentiated	09(52.94%)
	Poorly differentiated	04(23.52%)
3.	Signet ring adenocarcinoma	03(12%)
4.	Poorly differentiated SCC	01(4%)
5.	Poorly differentiated carcinoma	02(8%)
6.	Highly suspicious for malignancy	01(4%)
	Total	25

TABLE No. 7: DISTRIBUTION OF NEOPLASTIC LESIONS OF STOMACH

Among the neoplastic lesions in stomach, majority of the cases were of adenocarcinoma accounting to 68% of neoplastic lesions of stomach followed by signet ring adenocarcinoma accounting to 12%. There was only 1 case of benign neoplasm i.e. adenomatous polyp. One case of poorly differentiated adenocarcinoma was associated with candidiasis. Out of 2 cases of poorly differentiated carcinoma, in one case differential diagnosis of NHL was given. IHC (CK7 and CK20) staining was done. CK7 showed focal positivity and CK20 showed diffuse positivity indicating diagnosis of poorly differentiated adenocarcinoma of stomach.

TABLE No. 8: DISTRIBUTION OF LESIONS OF GASTROESOPHAGEAL

Sl. No	HISTOMORPHOLOGICAL PATTERN	NUMBER OF CASES
1.	Chronic non-specific inflammation	02(13.33%)
2.	Barrett's esophagus	01(6.66%)
3.	Hyperplastic polyp	01(6.66%)
4.	Moderately differentiated SCC	06(40%)
5.	Well differentiated adenocarcinoma	03(20%)
6.	Moderately differentiated adenocarcinoma	02(13.33%)
	Total	15

JUNCTION

Most common lesion at GEJ was moderately differentiated squamous cell carcinoma followed by adenocarcinoma.

Sl. No	HISTOMORPHOLOGICAL PATTERN	NUMBER OF CASES
1	Chronic non specific duodenitis	<i>(</i> 1(87) 30/()
1.	Chrome non-specific duodentits	41(07.23%)
2.	H. Pylori duodenitis	01(2.12%)
3.	Celiac disease	01(2.12%)
4.	Villous atrophy with crypt hyperplasia	02(4.25%)
5.	Well differentiated adenocarcinoma	01(2.12%)
6.	Normal histology	01(2.12%)
	Total	47

Majority of the cases in duodenum were of chronic non-specific duodenitis amounting to 87.23%.

PHOTOMICROGRAPHS



Fig 1: Photomicrograph of Barrett's esophagus (H&E stain 40x)



Fig 2: Photomicrograph of Barrett's esophagus (H&E stain 400x)



Fig 3: Photomicrograph of chronic gastritis with H. pylori infection (H&E stain 400x) Fig 4: Photomicrograph of H. pylori colonies in stomach (Giemsa stain 1000x)





Fig5: Photomicrograph of Inflammatory gastric polyp (H&E stain 100x)

(H&E stain 40x)

Fig6: Photomicrograph of Inflammatory gastric polyp (H&E stain 400x)

adenocarcinoma of stomach (H&E stain 40x)





Fig:9 Photomicrograph of Signet ring adenocarcinoma of stomach (H&E stain 400x)

Fig 10: Photomicrograph of Well differentiated SCC of esophagus with Candidiasis(H&E stain 100x)



Fig 11: Photomicrograph of Well differentiated SCC – esophagus with Candidal yeast forms and pseudohyphae (H&E stain 400x) Fig 12: Photomicrograph of Candidal yeast forms and pseudohyphae (PAS stain 1000x)



Fig 13: Photomicrograph of Moderately differentiated SCC of esophagus (H&E stain 100x)

Fig 14: Photomicrograph of Poorly differentiated SCC of esophagus (H&E stain 400x)



Fig 15: Photomicrograph of Celiac disease - duodenum (H&E stain 40x)



Fig 16: Photomicrograph of Well differentiated adenocarcinoma of duodenum - periampullary region (H&E stain 100x)



Fig 17: Photomicrograph of Poorly differentiated carcinoma (H&E stain 400x)

Fig 18: Photomicrograph of Poorly differentiated carcinoma showing focal positivity for CK7 (400x)



Fig:19 Photomicrograph of poorly differentiated carcinoma showing diffuse positivity for CK20 (40x) Fig:20 Photomicrograph of MALToma of stomach (H&E stain 400x)

DISCUSSION

Adequate clinical and endoscopic information is a fundamental part of adequacy and it strongly affects in the interpretation of biopsy. In the present study dysphagia, anorexia, vomiting, pain in abdomen, chronic diarrhoea, distension of abdomen and weight loss were the major presenting symptoms. In few cases history of hematemesis was noted. Similar presenting symptoms were reported in a study done Gulia SP *et al.*⁵ In their study they also found, presenting symptoms such as melena, constipation and bleeding per rectum, however these complaints were not noted in the present study.

In our study, total of 196 UGE biopsies were studied. Patients with upper GI lesions presented in the age group of 1st to 8th decade, the youngest patient was 04 years old and oldest was 87 years old. The mean age group was 44 years. Most common age group presenting with upper GI lesions was between 40 to 70 years accounting to 62%. Male to female ratio obtained in our study was 2.26:1

Gulia SP *et al* ⁵ studied 192 UGE biopsies. In their study, the youngest patient was of age 19 years and oldest was 75years. Male to female ratio in their study was 1.74:1.

Rashmi K *et al* ⁶⁰ studied 100 cases of UGE biopsies. In their study, highest incidence of endoscopic biopsies was in 4th and 5th decades and male to female ratio was 2.03:1. Findings of our study are correlating with the results of study done by Rashmi K *et al* .⁶⁰

In our study cases of endoscopic biopsies in male patients were more than in female patients. This could probably be due to the large number of male patients attending the outpatient department compared to the female patients, and increase in the number of gastrointestinal tract malignancies in males than females as stated by Rashmi k *et al* $.^{60}$

Gulia SP *et al* 5 studied a total of 192 UGE biopsies in which 12cases (6.25%) were from esophagus, 163 cases (84.05%) from stomach and 6 cases (3.64%) were from duodenum.

In a study done by Rashmi K *et al* 60 25 cases (25%) of esophageal biopsies, 68 cases (68%) of gastric biopsies and seven cases (7%) of duodenal biopsies were reported. In stomach, pylorus was the common site of biopsy.

In our study, out of 196 cases, 83(42.34%) were from esophagus, 47(23.97%) cases were from stomach, 49(25%) were from duodenum and 15(7.65%) were from gastroesophageal junction. One case was from esophagogastric anastomosis site in a case of post trans-hiatal esophagectomy accounting for 0.5%. In esophagus the most common site of biopsy was mid esophagus that comprised of 56.62% of esophageal biopsies. Next common site was lower esophagus. In stomach pyloric and pre-pyloric regions were the common sites of biopsy.

In studies done by Rashmi K *et al*,⁶⁰ and Gulia SP *et al*,⁵ number of gastric biopsies were more. However in our study, majority of cases were esophageal biopsies.

In our study cases of both non-neoplastic lesions and neoplastic lesions were 48.46% each. Our study showed 68.67% of neoplastic lesions and 26.5% of non-neoplastic lesions in esophagus. In stomach, neoplastic lesions were 52.08% and non-neoplastic lesions were 48.93%. In duodenum, non-neoplastic lesions (93.87%) were far more common than neoplastic lesions (2.04%). In GEJ, 73.33% cases were neoplastic and 26.66% cases were non-neoplastic...

In study done by Gulia SP *et al*, ⁵ 87.5% cases were inflammatory lesions and 6.25% cases were malignant lesions of esophagus and stomach and 5.62% cases had normal histology. In study done by Rashmi K *et al*, ⁶⁰ 56% cases were non-neoplastic and 44% cases were neoplastic. In study done by above authors, non-neoplastic lesions were higher than neoplastic lesions. However in our study overall percentage of neoplastic and non-neoplastic lesions was equal.

In our study, in esophagus, neoplastic lesions(68.67%) were more common than non-neoplastic lesions. Amongst the non-neoplastic lesions of esophagus, chronic non-specific esophagitis was the most common lesion accounting to 59.09% of non-neoplastic lesions. Our study findings are similar to the findings of other author's study of histomorphological spectrum of endoscopic biopsies.^{60, 61} Two cases of esophagitis in our study were associated with dysplasia, one was mild dysplasia and the other was moderate dysplasia. There were 2 cases (9.09%) of mild dysplasia, 4 cases (18.18%) of Barrett's esophagus and one case (4.54%) each of hyperplastic polyp, ciliated metaplasia and ulcer with granulation tissue.

Amongst the neoplastic lesions of esophagus, most common lesion in our study was SCC- moderately differentiated. The next common malignancy was adenocarcinoma. There were 5.26% cases of poorly differentiated carcinoma.

These findings are similar to study done by Pun CB *et al* ⁶². They studied a total of 106 esophageal carcinoma cases (57 endoscopic biopsies and 49 radical esophagectomy specimens). Their study revealed SCC as the most common malignancy occurring in esophagus followed by adenocarcinoma. Among SCC, moderately differentiated SCC was most common. There were 3.78% cases of undifferentiated carcinoma.

In study done by Rashmi K *et al*, ⁶⁰ all neoplastic esophageal lesions were malignant and all were SCC.

In our study, SCC was most common in the age group of 50 to 75 years and the most common site of occurrence was mid esophagus followed by lower esophagus which is similar to the finding of study done by Pun CB *et al* 62 where esophageal cancer was most common in the age range of 61 to 70 years. But the most common site of occurrence of SCC in their study was distal third of esophagus followed by mid esophagus.

In our study, in stomach neoplastic lesions (52.08%) were more than nonneoplastic lesions (48.93%). However in a study done by Rashmi K *et al*, 60 nonneoplastic lesions (68.33%) in stomach were more than neoplastic lesions (39.7%).

In our study, there were 41.66% cases of adenocarcinoma (including signet ring adenocarcinoma) of stomach, 39.58% cases of chronic gastritis. Two cases of chronic gastritis were associated with intestinal metaplasia.

Pailoor K *et al* 63 conducted a study to correlate histopathological diagnosis with endoscopy of 52 gastric biopsies. In their study, 55.76% cases were of adenocarcinoma of stomach, 34.61% cases were of gastritis. 3 cases of gastritis were associated with metaplasia.

Sultana A *et al* 64 studied 105 cases of gastric biopsies and correlated the endoscopic and histolologic findings. In their study there were 56.19% cases of adenocarcinoma, 36.19% cases of gastritis. Metaplasia was noted in 2 cases.

Our study findings of lesions of stomach were similar to the study done by Pailoor K *et al* 63 and Sultana A *et al* 64

In our study there was one case adenomatous polyp and one case of hyperplastic polyp. In study done by Rashmi K *et al* 60 there were 5 cases of adenomatous polyp and 3 cases of hyperplastic polyp.

In our study, Giemsa stain for H. pylori was done in all cases of chronic gastritis and chronic duodenitis. H. pylori was found in only 2 cases (10.5%) of chronic gastritis and in one case (2.38%) of chronic duodenitis. In study done by Rashmi K *et al*,⁶⁰ H. pylori positivity was seen in 7% cases of non-neoplastic lesions of stomach. Gulia SP *et al* ⁵ found H. pylori in 4.57% cases of non neoplastic lesions of stomach. Observations of our study were correlating with study done by Rashmi K *et al* ⁶⁰.

According to a study done by Loffeld RJLF *et al*,⁶⁵ the presence of H. pylori is decreasing due to a lower acquisition of the micro organism. According to study done Gulia SP *et al*, ⁵ H. pylori negative gastritis could be due to therapy for H. pylori eradication or failure to see organism in the tissue specimens.

H. pylori causes predominantly antral gastritis.³⁶ In many studies the prepyloric antrum was the preferred site of biopsy .⁴⁰ Genta & Graham performed a detailed topographic study of H. pylori in the stomach of untreated patients, and reported a sensitivity of 100% for a single biopsy taken from the angle of the stomach. The sensitivity of one distal antral biopsy was 96–97%. The sensitivity of two biopsies from virtually anywhere in the stomach was 100%.⁶⁶

In our study, we received only 2 biopsies from antrum and 3 from corpus of stomach. This might explain for the low rates of H. pylori positivity in our study. In our study, 2 cases of gastric biopsy were poorly differentiated carcinoma. In one case differential diagnosis of NHL was given. Immunohistochemistry (CK7 and CK20) staining was done. CK7 showed focal positivity and CK20 showed diffuse positivity indicating diagnosis of poorly differentiated adenocarcinoma of stomach. In one case which was reported as chronic non-specific gastritis on biopsy, gastrectomy was done as clinical features and endoscopic findings were highly suggestive of malignancy. The resected specimen on histopathology showed features of MALToma.

In a study done by Scott BB and Jenkins D,⁶ search for gastro-esophageal candidiasis was made by histological examination of all the endoscopic biopsies taken from 465 patients. Nineteen cases of candidiasis were found giving an overall incidence of 4%. There were 12 cases with esophageal candidiasis, two with both esophageal and gastric candidiasis, and five with gastric candidiasis.

In our study, candidiasis was associated with one case of well differentiated SCC of esophagus, one case of poorly differentiated adenocarcinoma of stomach and there was one case of pre-pyloric perforation associated with candidiasis.

The gastroesophageal junction (GEJ) is an anatomic area that represents the junction between the distal esophagus and the proximal stomach (cardia) 21 In our study there were 15 biopsies from GEJ in which SCC (40%) was the most common lesion followed by adenocarcinoma (33.33%) and chronic non-specific inflammation(13.33%). There was one case of Barrett's esophagus.

In a study done by Rashmi K *et al*,⁶⁰ there were seven cases of duodenal biopsies. Four patients had chronic non-specific duodenitis followed by one patient each with duodenal ulcer, well differentiated adenocarcinoma of ampulla of vater and tubular adenoma.

In a study done by Gulia SP *et al*, 5 there were 6 cases of duodenal biopsies and all 6 cases showed features of duodenitis.

In our study, we received 49 cases of duodenal biopsies in which there were 85.7% cases of chronic duodenitis. Giemsa stain was done in all cases of duodenitis but only one case (2.38%) of duodenitis showed positivity for H. pylori. There were 2 cases of villous atrophy with crypt hyperplasia. In one case of duodenal biopsy, diagnosis of celiac disease was suggested based on histological features of complete villous atrophy, crypt hyperplasia and intraepithelial lymphocytes. In one case endoscopic biopsy was taken from peri-ampullary region which was reported as well differentiated adenocarcinoma.

In our study majority of cases were of duodenitis which was similar to study done by other authors.^{5, 60}

CONCLUSION

Upper gastrointestinal tract disorders are one of the most commonly encountered problems in clinical practice. Upper GI endoscopy is a safe and well tolerated procedure. It helps in visualization of specific site of mucosal lesions. Endoscopy is incomplete without biopsy and histopathology is the gold standard for the diagnosis of endoscopically detected lesions. Endoscopic biopsy leads to an early diagnosis of various upper GI lesions and acts as a powerful diagnostic tool for early therapeutic decisions and management of the patients.

SUMMARY

A total of 196 UGIT endoscopic biopsies were studied received in the Department of Pathology, B.L.D.E. University's Shri B.M.Patil Medical College, Hospital & Research Centre, Bijapur from July 2010 to July 2014.

The histomorphological patterns of all the biopsies were studied and divided according to the site and nature of lesions.

Most of the patients with esophageal carcinoma presented with dysphagia and most of the duodenal biopsies were done to rule out malabsorption. Most of the carcinomas of UGIT endoscopically showed ulceroproliferative, nodular growth. Few cases showed stricture. Cases of esophagitis, gastritis and duodenitis did not show any significant finding on endoscopy in majority of the cases.

SCC of esophagus occurred more commonly in elderly age group i.e. between 50 to 75 years. Adenocarcinoma of stomach occurred more commonly in middle aged and elderly age i.e. between 30 to 70 years. However esophagitis, gastritis and duodenitis occurred in all age groups from 2^{nd} to 8^{th} decade.

Overall the numbers of neoplastic lesions were equal to non neoplastic lesions. Most commonly diagnosed non-neoplastic lesion in esophagus was chronic esophagitis and neoplastic lesion was SCC. Commonly diagnosed non-neoplastic lesion in stomach was chronic gastritis & and neoplastic lesion was adenocarcinoma. In duodenum, majority of cases were of chronic duodenitis.

Diagnostic interpretation limitations on endoscopic biopsies were encountered at times due to tiny biopsy material, handling and processing artifacts. These limitations can be overcome by taking multiple endoscopic biopsies.

Endoscopic biopsy leads to early diagnosis of various UGIT lesions. And thus helps in early therapeutic decisions & management of patients.

BIBLIOGRAPHY

- Olokoba AB, Bojuwoye BJ, Yusuf M, Olokoba LB, Wahab KW, Agaja SB *et al*. Common indications for upper gastro-intestinal tract endoscopy in ECWA Hospital, Egbe, Nigeria: a preliminary report. African Scientist 2006;7:165-9.
- Kazi JI, Alam SM, Kazi AM, Anwar A, Shamsi Z. Correlation of endoscopic and histological diagnosis in upper gastrointestinal lesions. J Pak Med Assoc 1990;40:281-3.
- Pasricha PJ .Gastrointestinal Endoscopy. In: Lee Goldman J, Clande Bennett. Cecil Textbook of Medicine. 21st ed. Philadelphia: W B Saunders; 2000. p. 649-50.
- 4) Kreuning J, Bosman FT, Kuiper G, Wal AM, Lindeman J. Gastric and duodenal mucosa in 'healthy' individuals. Journal of Clinical Pathology 1978;3:69-77.
- Gulia SP, Chaudhury M, Noorunnisa N, Balakrishnan CD, Balagurunathan K. Interpretation of upper gastrointestinal tract endoscopic mucosal biopsies – A study conducted in teaching hospital in Puducherry, India. International Journal of Medical Health Sciences 2012;1:17-24.
- Vidyavathi K, Harendrakumar ML, Lakshmana Kumar YC. Correlation of endoscopic brush cytology with biopsy in diagnosis of upper gastrointestinal neoplasms. Indian J Pathol Microbiol 2008;51:489-92.
- Nguyen VX, Nguyen VTL, Nguyen CC. Appropriate use of endoscopy in the diagnosis and treatment of gastrointestinal diseases: up-to-date indications for primary care providers. Int J Gen Med 2010;3:345–57.
- Dashan A, Rabah R. Correlation of endoscopy and histology in the gastroesophageal mucosa in children- are routine biopsies justified. J Clin Gastroenterol 2000;31:213-6.
- Sircus W, Flisk E, Craigs B, Fife. Milestones in the evolution of endoscopy: A short history. J R Coll Physicians Edinb 2003;33:124-34.
- Calder I, Ovassapian A, Calder N. John Logie Baird- Fibreoptic pioneer. J R Soc Med 2000;93:438-9.
- 11) Booth CC. A point of view-what has technology done to gastroenterology. Gut 1985;26:1088-94.
- 12) Kwon YS, Cho YS, Yoon TJ, Kim HS, Choi MG. Recent advances in targeted endoscopic imaging: Early detection of gastrointestinal neoplasms. World J Gastrointest Endosc 2012;4:57-64.
- 13) Serra S, Jani PA. An approach to duodenal biopsies. J Clin Pathol 2006;59:1133-50.
- 14) National Digestive Diseases Information Clearinghouse (NDDIC) .Upper GI endoscopy[Internet]. US: NIH Publication; updated 2014 May 7; cited 2014 April. Available from

http://www.digestive.niddk.nih.gov/ddiseases/pubs/upperendoscopy/index.aspx

- 15) Barkun A, Liu J, Carpenter S, Chotiprasidhi P, Chuttani R, Ginsberg G et al. Update on endoscopic tissue sampling devices. Gastrointest Endosc 2006;63:743-7.
- 16) Danesh BJZ, Burke M, Newman J, Aylott A, Whitfield P, Cotton PB. Comparison of weight, depth, and diagnostic adequacy of specimens obtained with 16 different biopsy forceps designed for upper gastrointestinal endoscopy. Gut 1985;26:227-31.
- 17) Fantin AC, Neuweiler J, Binek JS, Suter WR, Meyenberger C. Diagnostic quality of biopsy specimens: comparison between a conventional biopsy forceps and multibite forceps. Gastrointest Endosc 2001;54:600-4.

- 18) Kim CG. Tissue acquisition in gastric epithelial tumor prior to endoscopic resection. Clin Endosc 2013;46:436–40.
- 19) Malhotra V, Puri R, Chinna RS, Chawla LS, Sabharwal BD. Endoscopic techniques in the diagnosis of upper gastrointestinal tract malignancies: a comparison. Acta Cytol 1996;40:929-32.
- 20) Singh I. Text book of human histology with colour atlas and practical guide. 6th
 ed. New Delhi: Jaypee brothers; 2011. p.243-46.
- 21) Eroschenko VP. difiore's Atlas of histology with functional correlations. 11th ed.
 Baltimore: Lippincott Williams & Wilkins; 2008. p.263-302.
- 22) Rosai J. Rosai and Ackerman's Surgical pathology. 10th ed. New Delhi: Elsevier; 2011. p. 585-713.
- 23) Turner JR. The gastrointestinal tract. In:Kumar V, Abbas A K, Fausto N, Aster J C. Robbins and Cotran Pathologic basis of disease. 8th ed. New Delhi: Elsevier; 2010. p. 763-819.
- 24) Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Listrom MB, Rilke FO. Gastrointestinal pathology: an atlas and text. 2nd ed. Philadelphia: Lippincott-Raven; 1999. p. 31-153.
- 25) Zuberi BF, Faisal N, Quraishy MS, Afsar S, Kazi LAG, Kazim E. Correlation between clinical, endoscopic and histological findings at esophago-gastric junction in patients of gastroesophageal reflux disease. J Coll Physicians Surg Pak 2005;15(12):774-7.
- 26) Fu B, Rueda-Pedraza E. Non-neoplastic disorders of the esophagus. In:Lacobuzio-Donahue CA, Montgomery E, Goldblum JR. Gastrointestinal and liver pathology. A volume in the series: Foundations in diagnostic pathology. 2nd ed. Philadelphia: Elsevier saunders; 2012. p. 1-34.

- 27) Fiocca R, Mastracci L, Milione M, Parente P, Savarino V. Microscopic esophagitis and Barrett's esophagus: The histology report. Dig Liver Dis 2011;43:319–330
- 28) Brindley N, Sloan JM, McCallion WA. Esophagitis: optimizing diagnostic yield by biopsy orientation. Journal of pediatric gastroenterology & nutrition 2004;39:262-4.
- 29) Kasap E, Zeybel M, Asik G, Ayhan S, Yuceyar H. Correlation among standard endoscopy, narrow band imaging and histopathological findings in the diagnosis of nonerosive reflux disease. J Gastrointestin Liver Dis 2011;20:127-30.
- 30) Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-63.
- 31) Montgomery E. Tumors of esophagus. In:Lacobuzio-Donahue CA, Montgomery E, Goldblum JR. Gastrointestinal and liver pathology. A volume in the series: Foundations in diagnostic pathology. 2nd ed. Philadelphia: Elsevier saunders; 2012. p. 35-64.
- 32) Khandwalla HE, Graham DY, Kramer JR, Ramsey DJ, Duong PA, Green LK et al. Barrett's esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next. Am J Gastroenterol. 2014;109:178-82.
- 33) Sandick JWV, Lanschot JJBV, Kuiken BW, Tytgat GNJ, Offerhaus GJA, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.

- 34) Campbell F, Lauwers GY, Williams GT. Tumors of esophagus and stomach. In:
 Fletcher CDM. Diagnostic histopathology of tumors. 3rd ed. Philadelphia:
 Elsevier; 2007. p. 327-78.
- 35) Lisa M, Yerian, Goldblum JR. Esophagus. In: Mills SE, Carter D, Greenson JK, Reuter VE, Stoler MH. Sternberg's diagnostic surgical pathology. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2010. p. 1249-78.
- 36) Owen DA. The stomach. In: Mills SE, Carter D, Greenson JK, Reuter VE, Stoler MH. Sternberg's diagnostic surgical pathology. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2010. p.1279-1312.
- 37) Bhattacharya B. Non-neoplastic disorders of stomach. In:Lacobuzio-Donahue CA, Montgomery E, Goldblum JR. Gastrointestinal and liver pathology. A volume in the series: Foundations in diagnostic pathology. 2nd ed. Philadelphia: Elsevier saunders; 2012. p. 65-141.
- 38) Kacar F, Culhaci · N, Yukselen V, Meteog lu I, Dikiciog lu E, Levi E. Histologic demonstration of Helicobacter pylori in gastric biopsies: which is the best staining method? The Internet Journal of Pathology 2004; 3 (1). (www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpa/vol3n1/pylori.xl)
- 39) Rotimi O, Cairns A, Gray S, Moayyedi P, Dixon MF. Histological identification of Helicobacter pylori: comparison of staining methods. J Clin Pathol 2000;53:756–9.
- 40) Cohen H, Laine L. Endoscopic methods for the diagnosis of Helicobacter pylori. Aliment Pharmacol Ther 1997;11:3-9.
- 41) Akanda MR, Rahman AN. Comparative study of different methods for detection of Helicobacter pylori in gastric biopsies. Dinajpur Med Col J 2011 Jan;4:1-6.

- 42) Ahsan K, Hossain MZ, Uddin MR. Role of crush cytology for the detection of Helicobacter pylori in gastroduodenal diseases. J Dhaka Med Coll 2008;17:88-92.
- 43) Ahluwalia C, Jain M, Mehta G, Kumar N. Comparison of endoscopic brush cytology with biopsy for detection of Helicobacter pylori in patients with gastroduodenal diseases. Indian J Pathol Microbiol 2001;44:283-8.
- 44) Seth AK, Kakkar K, Manchanda K. Role of biopsy from gastric corpus in diagnosis of Helicobacter pylori infection in patients on acid suppression therapy. Med J Armed Forces India 2003;59:216-7.
- 45) Rubio CA. My approach to reporting a gastric biopsy. J Clin Pathol 2007;60:160–6.
- 46) Carmack SW, Genta RM, Graham DY and Lauwers GY. Management of gastric polyps: a pathology based guide for gastroenterologists. Gastroenterol Hepatol 2009;6:331-41.
- 47) Ang TL, Khor CJL, Gotoda T. Diagnosis and endoscopic resection of early gastric cancer. Singapore Med J 2010;5:93-100.
- 48) Chu KM, Kwok KF, Law S, et al. Patients with Helicobacter pylori positive and negative duodenal ulcers have distinct clinical characteristics. World J Gastroenterol 2005;11:3518-22.
- 49) Gonul CD, Bilge C, Gazi KA, Filiz K. Duodenal nodularity in children: A clinical and pathologic study of 17 cases. Indian J Pathol Microbiol 2011;54:312-7.
- 50) Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001;120:636–51.

- 51) Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity.Baillieres Clin Gastroenterol 1995;9:273–93.
- 52) Oberhuber G, Granditsch G, Vogelsang H. The histopathology of celiac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999;11:1185–94.
- 53) Prasad KK, Thapa BR, Nain CK, Singh K. The frequency of histologic variability of the duodenal mucosa in children with celiac disease. World J Pediatr 2010;6:60-4.
- 54) Mee AS, Burke M, Vallon AG, Newman J, Cotton PB. Small bowel biopsy for malabsorption: comparison of the diagnostic adequacy of endoscopic forceps and capsule biopsy specimens. BMJ 1985;291:769-72.
- 55) Mouzan MIE, Assiri AMA, Herbish ASA, Sohaibani MOA. Endoscopic duodenal biopsy in children. Saudi J Gastroenterol 2006;12:31-3.
- 56) Jass JR. Tumors of small and large intestines. In: Fletcher CDM. Diagnostic histopathology of tumors. 3rd ed. Philadelphia: Elsevier; 2007. P. 379-87.
- 57) Solej M, D'Amico S, Brondino G, Ferronato M, Nano M. Primary duodenal adenocarcinoma. Tumori 2008;94:779-86.
- 58) Lee CC, Ng WK, Lin KW, Lai TW, Li SM. Adenocarcinoma of the duodenum. Hong Kong Med J 2008;14:67-9.
- 59) Mullen JT, Wang H, Yao JC, Lee JH, Perrier ND, Pisters PWT et al. Carcinoid tumors of the duodenum. J Surg 2005;138:971-8.
- 60) Rashmi K, Horakerappa MS, Karar A, Mangala G. A study on histopathological spectrum of upper gastrointestinaltract endoscopic biopsies. International Journal of Medical Research & Health Sciences 2013;2:418-24.

- 61) Khan N, Shabbir G, Zarif M, Khattak MI. Upper gastrointestinal endoscopic assessment of patients presenting with dyspepsia. J Postgrad Med Inst 2007;21:212-6.
- 62) Pun CB, Aryal G, Basyal R, Shrestha S, Pathak T, Bastola S et al. Histological pattern of esophageal cancer at BP Koirala memorial cancer hospital in Nepal: a three year retrospective study. Journal of Pathology of Nepal 2012;2:277-81.
- 63) Pailoor K, Sarpangala MK, Naik RCN. Histopathological diagnosis of gastric biopsies in correlation with endoscopy – a study in a tertiary care center. Advance Laboratory Medicine International 2013;3:22-31.
- 64) Sultana A, Badruddoza SM, Rahman F. Correlation between endoscopic and histological findings in different gastroduodenal lesion and its association with Helicobacter pylori. Anwer Khan Modern Medical College Journal 2011;2:6-10.
- 65) Loffeld RJLF, Liberov B, Dekkers PEP. The changing prevalence of upper gastrointestinal endoscopic diagnoses: a single centre study. Neth J Med 2012;70:222-6.
- 66) Genta RM, Graham DY. Comparison of biopsy sites for the histopathological diagnosis of Helicobacter pylori: A topographic study of H. pylori density and distribution. Gastrointest Endosc 1994;40:342–5.
- 67) Scott BB, Jenkins D. Gastro-oesophageal candidiasis. Gut 1982;23:137-9.

ANNEXURE-I

ETHICAL CLEARANCE





B.L.D.E.UNIVERSITY'S SHRI.B.M.PATIL MEDICAL COLLEGE, BIJAPUR-586 103 INSTITUTIONAL ETHICAL COMMITTEE

INSTITUTIONAL ETHICAL CLEARANCE CERTIFICATE

The Ethical Committee of this college met on <u>18-10-2012</u> at <u>3-30pm</u> to scrutinize the Synopsis of Postgraduate Students of this college from Ethical Clearance point of view. After scrutiny the following original/corrected & revised version synopsis of the Thesis has been accorded Ethical Clearance. Title <u>"Spectrum of Wistomerphological patterns</u> <u>of upper Gestrointes time tract enloscopic</u> <u>Bropsies</u>"

20 Name of P.G. student_ Sneka TANALLAS

pathology

Name of Guide/Co-investigator Dr_ Surekha Araken'

na.

DR.TEJASWINI. VALLABHA CHAIRMAN INSTITUTIONAL ETHICAL COMMITTEE BLDEU'S, SHRI.B.M.PATIL MEDICAL COLLEGE, BIJAPUR.

Following documents were placed before E.C. for Scrutinization

Copy of Synopsis/Research project.
 Copy of informed consent form

Any other relevant documents.

ANNEXURE-II

SAMPLE INFORMED CONSENT FORM

TITLE OF THE PROJECT :	SPECTRUM OF HISTOMORPHOLOGICAL
	PATTERNS OF UPPER
	GASTROINTESTINAL
	TRACT ENDOSCOPIC BIOPSIES
GUIDE :	Dr. SUREKHA U. ARAKERI
	M.D. Pathology
POSTGRADUATE STUDENT:	Dr. SNEHA JAWALKAR

PURPOSE OF RESEARCH:

I have been informed that the present study will be done to know the morphological patterns and frequencies of lesions in upper GI endoscopic biopsies.

PROCEDURE:

I understand that after having obtained a detailed clinical history thorough clinical examination will be done and after that endoscopic biopsy will be done & will be sent for histopathological examination.

<u>RISK AND DISCOMFORTS</u>:

I understand that I may experience some pain and discomforts during the endoscopy procedure or during taking the biopsy. This is mainly the result of my condition and the procedures of this study are not expected to exaggerate these feelings which are associated with the usual course of treatment.

BENEFITS:

I understand that my participation in the study will have no direct benefit to me other than the potential benefit of the treatment.

CONFIDENTIALITY:

I understand that the medical information produced by this study will become a part of hospital records and will be subject to the confidentiality. Information of sensitive personal nature will not be part of the medical record, but will be stored in the investigations research file.

If the data are used for publication in the medical literature or for teaching purpose, no name will be used and other identifiers such as photographs will be used only with special written permission. I understand that I may see the photograph before giving the permission.

REQUEST FOR MORE INFORMATION:

I understand that I may ask more questions about the study at anytime; **Dr. SNEHA JAWALKAR** at the Department of Pathology is available to answer my questions or concerns. I understand that I will be informed of any significant new findings discovered during the course of the study, which might influence my continued participation. A copy of this consent form will be given to me to keep for careful reading.

REFUSAL OR WITHDRAWAL OF PARTICIPATION:

I understand that my participation is voluntary and that I may refuse to participate or may withdraw consent and discontinue participation in the study at any time without prejudice. I also understand that **Dr**. **SNEHA JAWALKAR** may terminate my participation in the study after she has explained the reasons for doing so.

INJURY STATEMENT:

I understand that in the unlikely event of injury to me resulting directly from my participation in this study, if such injury were reported promptly, the appropriate treatment would be available to me. But, no further compensation would be provided by the hospital. I understand that by my agreements to participate in this study and not waiving any of my legal rights.

I have explained to ______ the Purpose of the research, the procedures required and the possible risks to the best of my ability.

Dr. SNEHA JAWALKAR

Date

(Investigator)

STUDY SUBJECT CONSENT STATEMENT:

I confirm that **Dr. SNEHA JAWALKAR** has explained to me the purpose of research, the study procedure, that I will undergo and the possible discomforts as well as benefits that I may experience in my own language. I have been explained all the above in detail in my own language and I understand the same. Therefore I agree to give consent to participate as a subject in this research project.

(Participant)

Date

(Witness to signature)

Date

ANNEXURE-III

SCHEME OF CASE TAKING

1) Name	:	CASE NO	:
2) Age	:	IP NO	:
3) Sex	:	DOA	:
4) Religion	:	DOD	:
5) Occupation	:		
6) Residence	:		
7) Presenting Complaints	:		

9) Past History :

- 10) Personal History :
- 11) Family History :
- 12) Treatment History :

13) General Physical Examination

Pallor	present/absent
Icterus	present/absent
Clubbing	present/absent
Generalized Lymphadenopathy	present/absent
Anasarca	present/absent
Built	Poor/Average /Well
Nourishment	Poor / Average /Well
Ophthalmic examination:	

Vitals:-

PR	:	BP	:
RR	:	Temp	:

Weight :

Systemic Examination:

- i. Respiratory System
- ii. Cardiovascular System
- iii. Central Nervous System
- iv. Per abdomen examination

Provisional Diagnosis:

Investigations:

Hematological examination

Ultrasonography:

Endoscopy findings:

Histopathological examination:

Macroscopy:

Microscopy:

Special stains:

Final Diagnosis:

KEY TO MASTER CHART

EGAS	-	Esophagogastric anastomosis site
Dys	-	Dysphagia
Dyp	-	Dyspepsia
Vom	-	Vomiting
Drh	-	Diarrhea
Epi Pain	-	Epigastric pain
Epi Full	-	Epigastric fullness
Pain abd	-	Pain abdomen
Hem	-	Hematemesis
Ls st	-	Loose stools
Anx	-	Anorexia
LOA	-	Loss of appetite
Ср	-	Chest Pain
Chr	-	Chronic
Eso	-	Esophagus
Sto	-	Stomach
Mal	-	Malabsorbtion
Diff	-	Differentiated
Mod	-	Moderately
Ca	_	Carcinoma

MASTER CHART

1 Name 101 No. entroping Instance and and speech Method	Sl.No.	NAME	OPD/IPD No.	HPR No.	AGE	SEX	SITE OF BIOPSY	Clinical history	Clinical Diagnosis	Endoscopic Findings	HPR Diagnosis
1 Summer [144] $ $	1	Radhabai	12087	1911/10	52	F	E(m)	Dys	?Ca esophagus	Friable growth	Mod diff SCC
1 Soles Moore 1700 1800 0 0 0 Non- Non	2	Nagamma	144443	2095/10	70	F	E(1)	Dys	?Ca esophagus	Ulcerative, nodular, friable growth	Well diff SCC
1 Oxform 0.501 2.010 6.0 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 10000 10000 100000 $1000000000000000000000000000000000000$	3	Saliya Maniyar	12700	2106/10	30	F	G(p)	Vom	?Chr gastritis	Erosions	Chr non-specific gastritis
5 Sourha (TML) YML $P = 0$ <td>4</td> <td>Mallamma</td> <td>153847</td> <td>2274/10</td> <td>60</td> <td>F</td> <td>E(m)</td> <td>Dys</td> <td>?Ca esophagus</td> <td>Strictures with growth</td> <td>Well diff SCC</td>	4	Mallamma	153847	2274/10	60	F	E(m)	Dys	?Ca esophagus	Strictures with growth	Well diff SCC
A Make (PO) Street Product Product of the street Product P	5	Kasturibai	155342	2322/10	26	F	GEJ	Pain abd	?Barrett's esophagus	Grade 2 esophagitis	Chr non-specific esophagitis
1 Binger Hybrid State N M Binger Decomposition Consideration Model and State 3 Decomposition 2024	6	Madevi	15621	2598/10	55	F	E(m)	Dys	?Ca esophagus	Growth in esophagus	Well diff SCC
b Datagent 2016 25201 4 0 0 Mathemation Instant densities Other and model fields 0 Kindacke 27004 (Wall 0 0 Constant CD Instant CD Mathematication 10 Guardation 27004 (Wall 0 0 Data del MA Mathematication 11 Guardation 27004 (Wall 0 0 Participation Mathematication 12 Gastation 20044 6001 Final-Data National Mathematication National Mathematication National Mathematication 13 Mathematication 10 0 0 Data Columbication National Mathematication National Mathematication <td>7</td> <td>Basappa</td> <td>197466</td> <td>3010/10</td> <td>70</td> <td>М</td> <td>E(m)</td> <td>Dys</td> <td>?Ca esophagus</td> <td>Growth in esophagus</td> <td>Mod diff SCC</td>	7	Basappa	197466	3010/10	70	М	E(m)	Dys	?Ca esophagus	Growth in esophagus	Mod diff SCC
	8	Draxayani	20126	3282/10	46	F	D	Drh	Malabsorption	Loss of mucosal folds	Chr non-specific duodenitis
10 Gurgosbysp. 22994 33810 8 9 70 complying Goods in GC Mod off SC 12 15 Chean 20141 38130 16 16 160	9	Krishnabai	20309	3314/10	60	F	G(p)	Vom	?Ca stomach/Peptic ulcer	Ulcers & nodularity at pylorus	H. pylori gastritis
11 Sensitivi 20:00 38:10 81 F Gau Date Description Description Description 12 14: 50:00 20:01	10	Gurupadappa	223904	3358/10	50	М	GEJ	Dys	?Ca esophagus	Growth at GEJ	Mod diff SCC
12 I S Charging STR104 99170 B V Figure 1 Control with a c	11	Sunandabai	256369	3854/10	41	F	G(a)	Dyp	?gastritis	No significant findings	Chr non-specific gastritis
1) General 2425 98/30 i < i < i i i i <	12	L S Choragi	261814	3943/10	58	М	G(p)	Pain abd,Dst,Vom	?Ca stomach	Growth with ulcers	Mod diff adenocarcinoma
14 Nucle basendary 98494 40010 60 P CL 000000 Prophysical statutum Reards configure 16 Lidy,Kuur 2023 47010 4 M O O O Nucleon A Events of the fill of the fil	13	Gourabai	24254	3953/10	74	F	E(m)	Dys	?Ca esophagus	Ulceroproliferative growth	Poorly diff SCC
States-ave States-ave States Open in the probability of the probability	14	Neela Pattanshetty	284894	4261/10	65	F	E(1)	Dyp	GERD	Esophageal stricture	Barrett's esophagus
16 UbpKenn 9273 6710 4 M D Cle abs OCK (FIRD) Low of meson lights Cle abs Cle abs 18 Scoregate Idea 1270 1971	15	Siddawwa	26682	4260/10	60	F	G(f)	Dys	?Ca stomach	Ulcerated nodular friable growth	Mod diff adenocarcinoma
17 8 Norms Flacker 492 1011 8 M Gen, b Fig the Names, Names, Names Uterest other parts Poort off strengtson 19 Matangesh Brade 177 1971 Na East Names, Names Dong aff SC 19 Matangesh Brade 177 1771 Names, Names Dong aff SC Dong aff SC 10 Matangesh Brade 178 Names,	16	UdayKumar	26775	4273/10	4	М	D	Chr drh	CS/CF/IBD	Loss of mucosal folds	Celiac disease
18 Conseth 1770 1971 10 N Form Processor Forward and processor Processor of the stressor Processor of the stressor 19 Multicoxed 559 10011 5 M Goog Part off SC 21 Database 556 10011 5 M Goog Mod off Accessor 22 String M 7813 10101 6 F Goog Number of the strengther Loophage growth Mod off Accessor 23 String M 7813 11211 6 M Goo Part Accessor Yes and the strengther Loophage growth West aff SC 24 Stress 4044 12411 5 F E Data Yes and the stressor	17	Shivappa Hudedar	492	116/11	55	М	G(f)	Epi ful	?Ca Stomach, ?Ca pancreas with mets	Ulcerated nodular friable growth	Poorly diff adenocarcinoma
19 Multiangoal, bindar 4777 4741 40 M Eno Para Carcobaga Gene his discore Dealary 21 Deadawa 5539 10011 65 F Eron) Dy TX a explagat Explayat Explayat Explayat Explayat Explayat Modula Method Weil aff SCC 21 Shringh 7322 12511 65 F Eron) Dy TX a explayat Explayat Explayat Explayat Explayat Stranget	18	Gurunath	13770	199/11	70	М	E(m)	Dys	?Ca esophagus	Esophageal growth	Poorly diff SCC
Bergeng 48% 9001 35 M $Grgpo$ Part all The atomach Ubergenging and the second growth Model of advancement 21 Duskes 559 112511 65 Edited No Bergenging and the second growth Model and SCC 22 Skrivit M 7442 112511 64 Mo D Cree of the System Bergenging and the Second growth Weight and Second growth 24 Gangawa 665 122111 44 F Grig Part Model State and Model and Part If the deduking and the second growth State and the second growth Model and Second growth	19	Mallanagouda Biradar	4737	874/11	50	М	E(m)	Dys	?Ca esophagus	Growth with strictures	Poorly diff SCC
121 Dankswa 559 H0011 6 F Road Dys No. scoolages Houland growth Model SCC 22 Skink M 7422 112211 6 M D Ore drift Struct in address and structure and struct	20	Peerappa	4876	890/11	35	М	G(pp)	Pain abd	?Ca stomach	Ulceroproliferative growth	Mod diff adenocarcinoma
Image: Probability of the second s	21	Dundawwa	5549	1000/11	65	F	E(m)	Dys	?Ca esophagus	Esophageal growth	Mod diff SCC
21 Monissist Walkar 2222 1211 65 M D Grading Spraw No significant limiting Clin one-specific doctaria. 23 Gaugarova 685 12911 6 M D Din Ave. No Spraw Spraw Spraw Mile comparison on the spraw of t	22	Shivaji M	78423	1192/11	70	М	E(m)	Dys	?Ca esophagus	Esophageal growth	Well diff SCC
$\frac{1}{24}$ Gaugarva685 $\frac{1}{12}$ (21)68FGuGuThe bar waveThe second	23	Moulasaab Walikar	79252	1215/11	65	М	D	Chr drh	?Sprue	No significant finding	Chr non-specific duodenitis
25 Rem 0041 12411 9 M D Description Scart duces fields in 2nd Part H prior inductions 26 Struct 19201 19201 12 F F F(n) Dyn The prior prior induces in 2nd Part Part Part Part Part Part Part Part	24	Gangawwa	6845	1229/11	48	F	G(c)	Pain abd. vom	?Ca stomach	Ulceroproliferative growth	Signet ring adenocarcinoma
2 Santhá 94102 1221 5 F Em Dra Tác crosbases Mid sophasel aronh Wid dif SC 28 Unaxwa 11033 227111 74 F Em Dra Drakes Esophasel aronh Mod dif SC 28 Basamia 1524 25711 7.4 F Em Drakes Esophasel Esophasel Esophasel Esophasel Mod dif SC 30 Aunkaka Salouk 1526 27011 7.2 M GEI Drakes Ca coophagea Unerranted findle growth at GEI Mod dif SC 31 Isama Padat 135 20971 7.8 Mid Tim Price Padat Drakes Ca coophagea Growth at GEI Mod dif SC 32 Devi Dayal 20898 31711 7.8 F Em Drake Na coophagea Growth at GEI Mod dif SC Socialization Na dif SC Socialization Na dif SC Socialization Na dif SC Socialization Na dif SC Socialization	25	Ramu	6904	1274/11	9	М	D	Drh.vom	?Chr malabsorption	Scant duodenal folds in 2nd Part	H. pylori duodenitis
121 Jyoti Byokol 1153 122 F E0 Von Excepting Complexity Thy whice patch costs byots coplagas Charon-specific company 28 Unavava 1103 212711 F F E00 Dyr Na Androff Sector Sciencers with growth Model ISSC 29 Basamen 14384 257711 52 F F(m) Dyr The polyages Sciencers with growth Model ISSC 31 Intan Poddat 138 209711 52 M GEI Pyr The polyages Utermand trading growth Model ISSC 32 Der Dorgal 20853 315611 63 Moderation Der Trading Science Scien	26	Sarubai	84102	1292/11	55	F	E(m)	Dvs	?Ca esophagus	Mid esophageal growth	Well diff SCC
22 Unavera 11933 12711 14 F Ends Dys Text herebrages Esophage growth Modelaft SeC 30 Ambelas Saloak 152/6 228/11 72 F F F F F Modelas	27	Jvoti Bvokod		1853/11	22	F	E(I)	Vom	Esophagitis?Candidiasis	Tiny white patches over lower esophagus	Chr non-specific esophagitis
29 Resume 1424 25711 21 Hom Dys No. Exploylages Residues of the growth Mod diff SCC 30 Jamba Soluck 125 29511 49 M GPU Norm 7.25 Exploylages Upcreating fully growth GEU Mod diff SCC 31 Jamma Padar 135 29511 49 M GPU Norm 7.25 Exploylages Growth a GEU Mod diff SCC 32 Devs Dayal 20352 115511 40 D Clif dh Patron Daya Red patron Mod diff SCC Soluting patr	28	Umawwa	11933	2127/11	74	F	E(m)	Dvs	?Ca esophagus	Esophageal growth	Mod diff SCC
30 Anabals Saladia, 131 Frame Padar 132. Provide Saladia, 132 Description Padar 132. Description Padar 132. Description Padar 133. Description Padar 133. Description Padar 133. Description Padar 134. Description Padar 134. Description Padar 134. Description Padar Description Padar <thdescription padar<="" th=""> Description Padar<td>29</td><td>Basamma</td><td>14294</td><td>2557/11</td><td>52</td><td>F</td><td>E(m)</td><td>Dvs</td><td>?Ca Esophagus</td><td>Strictures with growth</td><td>Mod diff SCC</td></thdescription>	29	Basamma	14294	2557/11	52	F	E(m)	Dvs	?Ca Esophagus	Strictures with growth	Mod diff SCC
131 Imam Padar 133 29:01 59 M GEV Yeam ?C: soglappes Growth at GU Mod diff SC: 312 Devir Dipyot 20185 315:01 0.0 M F(m) Dpp Gastritis Robusteria Dispose Di	30	Ambadas Salonke	15246	2736/11	72	М	GEJ	Dvs.vom	?Ca Esophagus	Ulcerarated friable growth at GEJ	Mod diff adenocarcinoma
12. Devi Davia 298323 313511 62 M End Dep Grantis Fed path horse summonolmany inaction Burneth combanis 23. Bassman Hagar 20398 311711 75 F E(a) Dy NC cosphages Esophageal growth Mod diff SCC 34. Mailawa 20398 312711 75 N F E(a) Dy NC cosphages Growth neghtages Mod diff SCC 35. Subatrangup 21416 366711 75 N P(0) Dys NC cosphages Growth neghtages Mod diff SCC 37. Shankrappe Kadi 38111 45 M E(m) Dys NC acophages Strutters with growth Mod diff SCC 38 Batratt 25355 409711 48 F E(m) Dys NC acophages Utcratted growth Mod diff SCC 40 Panderang 47077 470141 46 M G(g) Pin achd, vom CC acophages Utcratted growth Mod dif	31	Iranna Paddar	135	2939/11	59	М	GEJ	Vom	? Ca esophagus	Growth at GEJ	Mod diff SCC
Basewari Haur 19755 2416 [1] 30 M D Chr.dn Pragastriss No significant findings. Chr.gon-pecific diodentials 34 Mallawaa 20048 417711 75 F F(m) Dys Y2 acophagas Ulcented doubt rinde growth Meld diff SCC 36 Sindarmappa 21416 366011 64 M E(m) Dys Y2 acophagas Ulcented doubt rinde growth Meld diff SCC 36 Sindarmappa 25541 31971 45 M F(m) Dys Y2 acophagas Girowth in esophagas Mol diff SCC 38 Bharat 26554 399511 24 M D Chr.dn Type Y2 acophagas Ulcenter could rindle growth Meld Midt SCC 40 Panabraig 24073 421641 425 M G(fK) F(m) Dys Y2 acophagas Ulcenter could rindle growth Mol diff abscccactions 41 Stanabati 045141 42551 6217 D F(Gir) Dys	32	Devi Daval	208352	3135/11	62	М	E(m)	Dvp	Gastritis Red patch above squamocolumn		Barrett's esophagus
34 Mallawan 29498 3417.11 25 F Emm Drs TC scorbargs Exophased growth Mod diff SCC 35 Soudaramppa 21416 5664.11 64 Fino Drs TC scorbargs Ukcrate durbul friding growth Mod diff SCC 36 Siddaramppa 25551 380.11 45 M Fino Drs TC scorbargs Nictures with growth Weil diff SCC 38 Bhaat 25554 39641 22 M D Ch eth Top No significant findings Ch ron-specific doolentifis 39 Kalabat 22055 40971 426 H D D No Weil diff SC No Malamma Ch ron-specific doolentifis 41 Sharabat 42051 428 45501 62 F G(F) Pain Ah, von Yc a sombagus Uccrated norbal ribide growth Mod diff adencarcinoma 42 Malamma Hirterint 2548 45501 65 F G(F) Din Ah, von <	33	Basavarai Hugar	19785	3416/11	30	М	D	Chr drh	Pan gastritis	No significant findings	Chr non-specific duodenitis
3 Somalinggrup 21416 3666/11 64 M F(m) Dyp Carsophagus Ulcentel anduit feable gowth Mod diff SC 26 Sidatramagn 225541 381011 25 M E(m) Dys Ta ecophagus Growth in scophagus Mod tiff SC 28 Bhart 265541 3995/11 22 M D Chr oh Space No significant finding Chr ons-specific duodentiis 39 Kalabai 22055 419111 48 B E(m) Dys Ta ecophagus Ulcerated growth Mod diff SC 40 Pandurang 24073 421611 46 M G(Kco) Hern Leiomvoma Multiple crosions in body and fundus Chr ons-specific duodintiis 41 Sharatabai V34111 425 M G(G) Pain Abd, von Ta scophagus Ulcerated modula frabbe growth Mod diff SC 42 Chaggands Sadwala 30191 470911 60 F E(m & 1) Dys Ta ecophagus Ulcerat	34	Mallawwa	230498	3417/11	75	F	E(m)	Dys	?Ca esophagus	Esophageal growth	Mod diff SCC
36 Siddarmanya 255541 389/11 75 M E(n) Dys Carcephages Growth in cophages Mod diff SCC 37 Shankrappa Bandi 288 M Left Dys Carcephages Strictures with growth Well diff SCC 38 Bhart 220554 399/11 22 M D Chr oth Type No significant findings Chr ons-precific duodentiis 39 Kalabai 22007 42/161 46 P Carcephages Ulcerated growth Mod diff SCC 41 Padurang 22/307 42/161 46 F G(R) Pain Adv Carcephages Ulcerated nodula frable growth Mod diff SCC 42 Malaman Hirman 22/484 45/011 0 F G(R) Dys Carcephages Ulcerated nodula frable growth Mod diff SCC 43 Charamannia 27/113 49/411 75 F E(n) Dys Carcephages Growth with strictures Mod diff SCC 44 <td< td=""><td>35</td><td>Somalingappa</td><td>21416</td><td>3666/11</td><td>64</td><td>М</td><td>E(m)</td><td>Dyp</td><td>?Ca esophagus</td><td>Ulcerated nodular friable growth</td><td>Mod diff SCC</td></td<>	35	Somalingappa	21416	3666/11	64	М	E(m)	Dyp	?Ca esophagus	Ulcerated nodular friable growth	Mod diff SCC
37 Shahzargo Bandi 989/11 4.8 M Emp Dys "Cac cophagus Stricures with growth Well diff SCC 38 Bharat 205534 999/11 24 M D Che cheh "Spine" No significant findings Che non-specific dividuatiis 40 Pandurang 24073 421611 46 M G(Rc) Hem Leionwana Multiple erosins in body and findus. Che non-specific dividuatiis 41 Shatabai V/411 43811 63 F G(Rc) Dys "Ca cophagus Ulcerated nodular findus growth Mod diff SCC 42 Chagandai Sadivala 30159 470011 60 F G(Rc A) Dys "Ca cophagus Esophagus Esophagus <td< td=""><td>36</td><td>Siddaramappa</td><td>255541</td><td>3819/11</td><td>75</td><td>М</td><td>E(1)</td><td>Dys</td><td>?Ca esophagus</td><td>Growth in esophagus</td><td>Mod diff SCC</td></td<>	36	Siddaramappa	255541	3819/11	75	М	E(1)	Dys	?Ca esophagus	Growth in esophagus	Mod diff SCC
38 Barat 226534 3995/11 22 M D Chr drh Spres No significant findings Chr non-specific doudentis 39 Kalabai 23205 4019/11 48 F Em) Dys "Ca coophagus Ulcerated growth Moltiple crossion in body and fundus Chr non-specific doudentis 40 Pandurang 24073 4216/11 46 M G(f&c) Hem Leiomyoma Multiple crossion in body and fundus Chr non-specific doudentis 41 Shantabai V34/11 45 E(m & L) Dys "Ca coophagus Ulcerator doubt rabs growth Mol diff adencacrimona 42 Malamar Hiremant 25184 450711 0 F E(m) Dys "Ca coophagus Growth with strictures Mod diff SCC 43 Chandrappe Hikkonguli 0.1.nn 2512 70 M E(m) Dys "Ca coophagus Nodular growth Mod diff SCC 44 Rannarma 1611 28012 M D Vom Aganglinotosis of	37	Shankrappa Bandi		3881/11	45	М	E(m)	Dys	?Ca esophagus	Strictures with growth	Well diff SCC
39Kalabai223034019(1)48FE(m)Dys $?Ca esophagus$ Ulcerated growthMod diff SCC40Pandurang240734216/1146MG(f&c)HenLcionryonaMultiple crosions in body and fundusChr non-specific gastrilis41ShattabaiV/4111428/1162FG(F)Pain Add, vom $?Ca stomachUlcerative nodular fishel growthMod diff adexocarinoma42Malanna Hiremat2548445501150FE(m & I)Dys?Ca esophagusGrowth with stricturesMod diff SCC44Sharanamma2211349441175FE(I)Dys?Ca esophagusGrowth with stricturesMod diff SCC45Chandrapa Hikkonguili01-Jan2511270ME(m)Dys?Ca esophagusNodaer growthMod diff SCC46Ranolppa16112801263ME(m)Dys?Ca esophagusUlcerHighly supcicos for malignancy47Kashinath14742931220MDVomA assophagusUlcerHighly supcicos for malignancy48Pareppe Biabatti190173371224MDChr drhTropical sprueLoss of mocioial folkVillos actoply with reyr bryperplasia50Maleppa Binadar190824371244MG(g)DypGastrifisNo significant findingChr on-specific doadnifis51Sidappa Binadar19082437$	38	Bharat	265534	3995/11	22	М	D	Chr drh	?Sprue	No significant findings	Chr non-specific duodenitis
40 Pandurang 24073 $4216'11$ 46 M $G(kE_C)$ HemLeionyomaMultiple crosions in body and fundus.Chr non-specific gastritis 41 Malama Hiremat 25484 $4250'11$ 62 F $G(kE)$ Pain Abd, vom'Ca esophagusUtcerative nodular friable growthMod diff adencacinoma 42 Malama Hiremat 25484 $450'11$ 60 FEGEDys'Ca esophagusUtcerative nodular friable growthMod diff SCC 43 Chaganaba Sadivala 301591 $470'11$ 60 FEGEDys'Ca esophagusEsophagua strictures with growthMod diff SCC 44 Shanrahma 2512 70ME(m)Dys'Ca esophagusNodular growthMod diff SCC 46 Ranolappa1611 $280'12$ 63ME(m)Dys'Ca esophagusUtcerHighly suspicious for malignarcy 47 Kashinath1474 $23'12$ 0MDOramAggagionosis of duodenumDuodenum dilated upto 3rd partInadecate for opinion 48 Parepora Balabatti19017 33712 24MDChr drhTimone gland hypertrophyNo significant findingChr non-specific gastritis 50 Maleppa Bindar1908 $482'12$ 18MDL st'Rochers'MalabsorptionNo significant findingChr non-specific gastritis 51 Sidappa Mandeep1726 $370'12$ 18MDL st'Rochers'Malabsorpt	39	Kalabai	23205	4019/11	48	F	E(m)	Dys	?Ca esophagus	Ulcerated growth	Mod diff SCC
41ShantabaiV/34/11428/1162FG(F)Pain Abd, von%Ca stomachUlcerative nodular friable growthMod diff adenocarcinoma42Mallamma Hiremat254844500/150FE(m & L)Dys%Ca esophagusUlcerated nodular friable growthPoorly diff SCC43Chaganabi Sadwala301591470/1160FGEIDys%Ca esophagusGrowth with stricturesMod diff SCC44Sharanamma27113494/1175FE(D)Dys%Ca esophagusEsophageal strictures with growthMod diff SCC45Chandrappa Hikongui101-Jan25/1270ME(m)Dys%Ca esophagusUlcerHighly suspicious for malignancy47Kashmath1474293/1220MDVomAganglinonsis of duodenumDuodenum fliated upto 3rd partInadequate for opinon48Parepre Balabati19017371/1224MDChr drh?Brunner gland hypertrophyNo significant findingChr non-specific duodenitis50Makepp Biradar19084681218MDChr drh?Brunner gland hypertrophyNo significant findingChr non-specific duodenitis51Sidappa Manderg1726370/1248MG(g)Pain abdGastriis & Guodena JohypesisPolypInflamatory gastri polyp52Kamar Dudgi2069376/1213MDL s st?Kochs ?MalaborptionNo signifi	40	Pandurang	24073	4216/11	46	М	G(f&c)	Hem	Leiomvoma	Multiple erosions in body and fundus	Chr non-specific gastritis
42Mallamma Hiremat2548445501150F $E(m, \&)$ Dys?Ca esophagusUlcerated nodular friable growthPoorty diff SCC43Chaganaba Sadrwala301591470971160FGEJDys?Ca esophagusGrowth with stricturesMod diff SCC44Sharanamma2711349441175FE(I)Dys?Ca esophagusExophageal strictures with growthMod diff SCC45Chandrappa Hikkoonguli01-Jan25/1270ME(m)Dys?Ca esophagusNoderUlcerHighly suspicious for malignancy46Ranolappa1611280/1263ME(m)Dys?Ca esophagusUlcerHighly suspicious for malignancy47Kashinath1474293/1224MDChr drhTonner sequelLoss of muccoal foldsViluos atrophy with crypt hyperplasia48Pareppa Bialabatti1901737/1224MDChr drhTonner sequel hypertrophyNo significant findingChr non-specific doudenitis50Maleppa Biradar19982427/1244MG(a)DypGastritisAo significant findingsChr non-specific doudenitis51Sidappa Mandeep1726370/1248MDL st?kocks "MalabsorptionNo significant findingsChr non-specific doudenitis53Vittal Logavi2069376/1213MDL st?kocks "MalabsorptionLoss of muccoal folds<	41	Shantabai	V/34/11	4285/11	62	F	G(F)	Pain Abd, vom	?Ca stomach	Ulcerative nodular friable growth	Mod diff adenocarcinoma
43 Chaganabai Sadiwala 301591 4709/11 60 F GEJ Dys ?Ca esophagus Growth with strictures Mod diff SCC 44 Sharanamma 27113 4944/11 75 F E(I) Dys ?Ca esophagus Esophageal strictures with growth Mod diff SCC 46 Ranolappa 1611 28/12 70 M E(m) Dys ?Ca esophagus Nodular growth Mod diff SCC 47 Kashinath 1474 29312 20 M D Chr drh Tropical sprue Loss of muccoid folds Villous atrophy with roy thy hyperplasia 48 Parepa Balabati 19108 4631/12 18 M D Chr drh ?Brunner gland hypertrophy No significant finding Chr on-specific duodeniits 50 Maleppa Biradar 19082 42712 44 M G(a) Dyp Gastritis No significant finding Chr on-specific gastritis 51 Sidappa Mandeep 1762 37/12 48 M G(p) <t< td=""><td>42</td><td>Mallamma Hiremat</td><td>25484</td><td>4550/11</td><td>50</td><td>F</td><td>E(m & 1)</td><td>Dys</td><td>?Ca esophagus</td><td>Ulcerated nodular friable growth</td><td>Poorly diff SCC</td></t<>	42	Mallamma Hiremat	25484	4550/11	50	F	E(m & 1)	Dys	?Ca esophagus	Ulcerated nodular friable growth	Poorly diff SCC
44 Sharananna 27113 4944/11 75 F E(I) Dys ?Ca esophagus Esophageal strictures with growth Mod diff SCC 45 Chandrappa Hikkonguli 01-Jan 25/12 70 M E(m) Dys ?Ca esophagus Nodular growth Mod diff SCC 46 Ranolappa 1611 28/012 20 M D Vint Accephagus Ulcer Highly suppicious for malignancy 47 Kashinath 1474 2931/2 20 M D Vint Accephagus Ulcer Highly suppicions for duodenum Dademut diated upto 3rd part Inadequate for opninon 48 Parepa Balabatti 19017 337/12 24 M D Chr drh ?Buner partice Loss of mucosal folds Villous anophy with crypt hyperplasia 50 Maleppa Binadar 19082 427/12 44 M G(a) Dy Gastrifis & duodenal polyposis Polyp Inflamatory gastrific olypt pills 51 Sitdappa Mandeep 1726 37/612	43	Chaganabai Sadiwala	301591	4709/11	60	F	GEJ	Dys	?Ca esophagus	Growth with strictures	Mod diff SCC
45 Chandrappa Hikkongulli 01-Jan 25/12 70 M E(m) Dys ?Ca csophagus Nodular growth Mod diff SCC 46 Ranolappa 1611 280/12 63 M E(m) Dys ?Ca csophagus Ulcer Highly suspicious for omaingancy 47 Kashinah 1474 293/12 0 M D Vom Agarghinosis of duodenum Duodenum dilated upto 3rd part Inadequate for opinion 48 Pareppa Balabati 19017 337/12 24 M D Chr drh Tronical sprue Loss of macosal folds Villous atrophy with crypt hyperplasia 49 Asif Nadaf 19108 468/12 18 M D Chr drh Tronical sprue Loss of macosal folds Villous atrophy with crypt hyperplasia 51 Sidappa Mandeep 1726 370/12 48 M G(p) Paiu abd Gastritis & duodenal polyposis Polyp Inflamatory gastric polyp 53 Vittal Logavi 2069 376/12 13 M	44	Sharanamma	27113	4944/11	75	F	E(1)	Dys	?Ca esophagus	Esophageal strictures with growth	Mod diff SCC
46 Ranolappa 1611 280/12 63 M E(m) Dys ?Ca esophagus Uler Highly suspicious for malignancy 47 Kashinath 1474 293/12 20 M D Vom Aganglionosis of duodenum Duodenum dilated upto 3rd part Inadeugate for opinion 48 Pareppa Balabatti 19017 337/12 24 M D Chr drh Tropical sprue Loss of mucosal folds Villous atrophy with crypt hyperplasia 49 Asif Nadaf 19108 468/12 18 M D Chr drh ?Brunner gland hypertrophy No significant finding Chr non-specific duodentits 50 Maleppa Biradar 19082 427/12 44 M G(a) Dyp Gastritis & duodenal polyposis Polyp Inflamatory gastric polyp 51 Sidappa Mandeep 1726 370/12 48 M G(p) Pain abd.vom ?Ca stomach Ulceroproliferative growth Poorly diff SCC 54 Sangeetha 111.133 607/12 45 M	45	Chandrappa Hikkongulli	01-Jan	25/12	70	М	E(m)	Dys	?Ca esophagus	Nodular growth	Mod diff SCC
47Kashinath1474293/1220MDVonAganglionosis of duodenumDuodenum dilated upto 3rd partInadequate for opinion48Pareppa Balabatti19017337/1224MDChr drhTropical sprueLoss of mucosal foldsVillous atrophy with crypt hyperplasia49Asif Nadaf19108468/1218MDChr drh?Brunner gland hypertrophyNo significant findingChr non-specific duodenitis50Maleppa Biradar19082427/1244MG(a)DypGastritisNo significant findingChr non-specific gastritis51Sidappa Mandeep1726370/1248MG(p)Paiu abdGastritis & duodenal polyposisPolypInflamatory gastric polyp52Kumar Dudgi2069376/1213MDL s st?Kochs?MalabsorptionNo significant findingChr non-specific duodenitis53Vitral Logavi2099408/1262MG(p)Pain abd,vom?Ca stomachUlceroproliferative growthPoorly diff SCC54Sangeetha111.126660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific gastritis55Jaibunissa111.126754/1255MG(pp)Pain abd,vom?Ca esophagusNodular growthMod diff SCC58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant finding </td <td>46</td> <td>Ranolappa</td> <td>1611</td> <td>280/12</td> <td>63</td> <td>М</td> <td>E(m)</td> <td>Dys</td> <td>?Ca esophagus</td> <td>Ulcer</td> <td>Highly suspicious for malignancy</td>	46	Ranolappa	1611	280/12	63	М	E(m)	Dys	?Ca esophagus	Ulcer	Highly suspicious for malignancy
48Parepa Balabatii19017337/1224MDChr drhTropical sprueLoss of mucosal foldsVillous atrophy with crypt hyperplasia49Asif Nadaf19108468/1218MDChr drh?Brunner gland hypertrophyNo significant findingChr non-specific duodenitis50Maleppa Biradar19082427/1244MG(a)DypGastritisNo significant findingChr non-specific gastritis51Sidappa Mandeep1726370/1213MDLs st?Kochs ?MalabsorptionNo significant findingsChr non-specific duodenitis52Kumar Dudgi2069376/1213MDLs st?Kochs ?MalabsorptionNo significant findingsChr non-specific duodenitis53Vittal Logavi2099408/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodenitis54Sangetha111L15660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodenitis55Jaibunissa111L26754/1255MG(pp)Pain abd.vom?Ca stomachNo significant findingChr non-specific duodenitis57Gangavya11193920/1262ME(m)Dyp?Ca stomachNo significant findingsInadequate for opinion59Sidamma111L26754/1255MG(p)Pain abd.vom?Ca scophagusNodular growt	47	Kashinath	1474	293/12	20	М	D	Vom	Aganglionosis of duodenum	Duodenum dilated upto 3rd part	Inadequate for opinion
49Asif Nadaf19108468/1218MDChr drh?Brunner gland hypertrophyNo significant findingChr non-specific duodenitis50Maleppa Biradar19082427/1244MG(a)DypGastritisNo significant findingChr non-specific gastritis51Sidappa Mandeep1726370/1248MG(p)Paiu abdGastritis & duodenal polyposisPolypInflamatory gastric polyp52Kumar Dudgi2069376/1213MDLs st?Kochs ?MalabsorptionNo significant findingsChr non-specific duodenitis53Vittal Logavi2099408/1262MG(p)Pain abd,vom?Ca stomachUlceroproliferative growthPoorly diff SCC54Sangeetha111.132660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodenitis55Jabunissa111.152660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific gastritis56A R Sonagi111.26754/1255MG(pp)Pain abd,vom?Ca stomachNo significant findingsInadequate for opinion57Gangayva111.93920/1262ME(m)Dyp?Ca stomachNo significant findingsInadequate for opinion59Sidamma111.9291/1255FE(l)Dyp?Ca esophagusNo significant findingChr conspecific d	48	Pareppa Balabatti	19017	337/12	24	М	D	Chr drh	Tropical sprue	Loss of mucosal folds	Villous atrophy with crypt hyperplasia
50Malepa Biradar19082427/1244MG(a)DypGastritisNo significant findingChr non-specific gastritis51Sidappa Mandeep1726370/1248MG(p)Pain abdGastritis & duodenal polyposisPolypInflamatory gastric polyp52Kumar Dudgi2069376/1213MDLs st?Kochs ?MalabsorptionNo significant findingChr non-specific duodenitis53Vittal Logavi2099408/1262MG(p)Pain abd.vom?Ca stomachUlceroproliferative growthPoorly diff SCC54Sangeetha11L153607/1228FE(m)DypEsophagitisGrade 2 esophagitisChr non-specific duodenitis55Jaibunissa11L126660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific gastritis57Gangava11L93920/1262ME(m)Dyp?Ca stomachNo significant findingsInadequate for opinion58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingChr esophagus60Hazifa19196944/1265ME(m)Dyp?Ca esophagusEsophageal strictureWell diff SCC61Siddappa19210986/1254MG(p)Pain abdPrepyloric ulcer ?Ca stomachNo significant findingChr esophagus62Gangamma<	49	Asif Nadaf	19108	468/12	18	М	D	Chr drh	?Brunner gland hypertrophy	No significant finding	Chr non-specific duodenitis
51Sidappa Mandeep1726370/1248MG(p)Paiu abdGastritis & duodenal polyposisPolypInflamatory gastric polyp52Kumar Dudgi2069376/1213MDLs st?Kochs ?MalabsorptionNo significant findingsChr non-specific duodenitis53Vittal Logavi2099408/1262MG(p)Pain abd,vom?Ca stomachUlceroproliferative growthPoorly diff SCC54Sangeetha111.133607/1228FE(m)DypEsophagitisGrad 2 esophagitisChr non-specific duodenitis55Jaibunissa111.152660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodenitis56A R Sonagi111.26754/1255MG(pp)Pain abd,vom?Ca stomachNo significant findingChr non-specific duodenitis57Gangayya111.193920/1262ME(m)Dyp?Ca esophagusNo dular growthMod diff SCC58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingInadequate for opinion59Sidamma111.29917/1255FE(l)Dyp?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa1910986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppu	50	Maleppa Biradar	19082	427/12	44	М	G(a)	Dyp	Gastritis	No significant finding	Chr non-specific gastritis
52Kumar Dudgi2069376/1213MDLs st?Kochs ?MalabsorptionNo significant findingsChr non-specific dudentitis53Vittal Logavi2099408/1262MG(p)Pain abd,vom?Ca stomachUlceroproliferative growthPoorly diff SCC54Sangeetha11L133607/1228FE(m)DypEsophagitisGrade 2 esophagitisChr non-specific duodentitis55Jaibunissa11L152660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodentitis56A R Sonagi11L26754/1255MG(pp)Pain abd,vom?Ca stomachNo significant findingChr non-specific gastritis57Gangayya11L93920/1262ME(m)Dyp?Ca stomachNo significant findingsInadequate for opinion58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingsInadequate for opinion59Sidamma11L92917/1255FE(I)Dyp?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer ?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod	51	Sidappa Mandeep	1726	370/12	48	М	G(p)	Paiu abd	Gastritis & duodenal polyposis	Polyp	Inflamatory gastric polyp
53Vittal Logavi2099408/1262MG(p)Pain abd,vom?Ca stomachUlceroproliferative growthPoorly diff SCC54Sangeetha11L133607/1228FE(m)DypEsophagitisGrade 2 esophagitisChr non-specific esophagitis55Jaibunissa11L152660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodenitis56A R Sonagi11L26754/1255MG(pp)Pain abd,vom?Ca stomachNo significant findingChr non-specific gastritis57Gangayya11L93920/1262ME(m)Dyp?Ca esophagusNodular growthMod diff SCC58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingsInadequate for opinion59Sidamma11L92917/1255FE(l)Dyp?Ca esophagusEsophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma19321290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193411337/1255MG(c)Vom,drhGastritisGrowth below upper esophageal sphincterPoorly dif	52	Kumar Dudgi	2069	376/12	13	М	D	Ls st	?Kochs ?Malabsorption	No significant findings	Chr non-specific duodenitis
54Sangeetha11L133607/1228FE(m)DypEsophagitisGrade 2 esophagitisChr non-specific esophagitis55Jaibunissa11L152660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodenitis56A R Sonagi11L26754/1255MG(pp)Pain abd,vom?Ca stomachNo significant findingChr non-specific gastritis57Gangayya11L93920/1262ME(m)Dyp?Ca esophagusNodular growthMod diff SCC58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingsInadequate for opinion59Sidamma11L92917/1255FE(l)Dyp?Ca esophagusEsophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlcer on specific duodenitis64Chandrakant19341133/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis65Bhagawwa67461431/1265FE(m)Dys?Ca esophagusGrowth below upper esophageal sphincterPoorly diff Ca. DD:Small cel	53	Vittal Logavi	2099	408/12	62	М	G(p)	Pain abd,vom	?Ca stomach	Ulceroproliferative growth	Poorly diff SCC
55Jaibunissa11L152660/1265FDChr drh?MalabsorptionLoss of mucosal foldsChr non-specific duodenitis56A R Sonagi11L26754/1255MG(pp)Pain abd,vom?Ca stomachNo significant findingChr non-specific gastritis57Gangayya11L93920/1262ME(m)Dyp?Ca esophagusNodular growthMod diff SCC58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingsInadequate for opinion59Sidamma11L92917/1255FE(I)Dyp?Ca esophagusEsophageal strictureWell diff SCC60Hazifa19196944/1265ME(m)Vom?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193431334/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis64Chandrakant193441337/1255MG(c)Vom,drhGastritisGastritisChr on-specific gastritis65Bhagawwa <td< td=""><td>54</td><td>Sangeetha</td><td>11L133</td><td>607/12</td><td>28</td><td>F</td><td>E(m)</td><td>Dyp</td><td>Esophagitis</td><td>Grade 2 esophagitis</td><td>Chr non-specific esophagitis</td></td<>	54	Sangeetha	11L133	607/12	28	F	E(m)	Dyp	Esophagitis	Grade 2 esophagitis	Chr non-specific esophagitis
56A R Sonagi11L26754/1255MG(pp)Pain abd,vom?Ca stomachNo significant findingChr non-specific gastritis57Gangayya11L93920/1262ME(m)Dyp?Ca esophagusNodular growthMod diff SCC58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingsInadequate for opinion59Sidamma11L92917/1255FE(I)Dyp?Ca esophagusEsophageal strictureWell diff SCC60Hazifa19196944/1265ME(m)Vom?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193431334/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis64Chandrakant193441337/1255MG(c)Vom,drhGastritisGastritisChr non-specific gastritis65Bhagawwa67461431/1265FE(m)Dys?Ca esophagusGrowth below upper esophageal sphincterPoorly diff Ca. DD:Small cell ca	55	Jaibunissa	11L152	660/12	65	F	D	Chr drh	?Malabsorption	Loss of mucosal folds	Chr non-specific duodenitis
57Gangayya11L93920/1262ME(m)Dyp? Ca esophagusNodular growthMod diff SCC58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingsInadequate for opinion59Sidamma11L92917/1255FE(l)Dyp?Ca esophagusEsophageal strictureWell diff SCC60Hazifa19196944/1265ME(m)Vom?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193431334/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis64Chandrakant193441337/1255MG(c)Vom,drhGastritisGastritisGastritisChr non-specific gastritis65Bhagawwa67461431/1265FE(m)Dys?Ca esophagusGrowth below upper esophageal sphincterPoorly diff Ca. DD:Small cell ca	56	A R Sonagi	11L26	754/12	55	М	G(pp)	Pain abd,vom	?Ca stomach	No significant finding	Chr non-specific gastritis
58Bhuvaneshwari19193936/1274FDChr drhMalabsorptionNo significant findingsInadequate for opinion59Sidamma11L92917/1255FE(I)Dyp?Ca esophagusEsophageal strictureWell diff SCC60Hazifa19196944/1265ME(m)Vom?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193431334/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis64Chandrakant193441337/1255MG(c)Vom,drhGastritisGastritisChr non-specific gastritis65Bhagawwa67461431/1265FE(m)Dys?Ca esophagusGrowth below upper esophageal sphincterPoorly diff Ca. DD:Small cell ca	57	Gangayya	11L93	920/12	62	М	E(m)	Dyp	? Ca esophagus	Nodular growth	Mod diff SCC
59Sidamma11L92917/1255FE(l)Dyp?Ca esophagusEsophageal strictureWell diff SCC60Hazifa19196944/1265ME(m)Vom?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193431334/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis64Chandrakant193441337/1255MG(c)Vom,drhGastritisGastritisGastritisChr non-specific gastritis65Bhagawwa67461431/1265FE(m)Dys?Ca esophagusGrowth below upper esophageal sphincterPoorly diff Ca. DD:Small cell ca	58	Bhuvaneshwari	19193	936/12	74	F	D	Chr drh	Malabsorption	No significant findings	Inadequate for opinion
60Hazifa19196944/1265ME(m)Vom?Ca esophagusNo significant findingChr esophagitis with moderate dysplasia61Siddappa19210986/1254MG(p)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193431334/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis64Chandrakant193441337/1255MG(c)Vom,drhGastritisGastritisGastritis65Bhagawwa67461431/1265FE(m)Dys?Ca esophagusGrowth below upper esophageal sphincterPoorly diff Ca. DD:Small cell ca	59	Sidamma	11L92	917/12	55	F	E(1)	Dyp	?Ca esophagus	Esophageal stricture	Well diff SCC
61Siddappa19210986/1254MG(pp)Pain abdPrepyloric ulcer /?Ca stomachNo significant findingUlcer with suppurative necrosis62Gangamma193281290/1266FE(m)DysCa esophagusUlceroproliferative growthMod diff SCC63Jayashree193431334/1244FDChr drhMalabsorptionNo significant findingsChr non-specific duodenitis64Chandrakant193441337/1255MG(c)Vom,drhGastritisGastritisChr non-specific gastritis65Bhagawwa67461431/1265FE(m)Dys?Ca esophagusGrowth below upper esophageal sphincterPoorly diff Ca. DD:Small cell ca	60	Hazifa	19196	944/12	65	М	E(m)	Vom	?Ca esophagus	No significant finding	Chr esophagitis with moderate dysplasia
62 Gangamma 19328 1290/12 66 F E(m) Dys Ca esophagus Ulceroproliferative growth Mod diff SCC 63 Jayashree 19343 1334/12 44 F D Chr drh Malabsorption No significant findings Chr non-specific duodenitis 64 Chandrakant 19344 1337/12 55 M G(c) Vom,drh Gastritis Gastritis Chr non-specific gastritis 65 Bhagawwa 6746 1431/12 65 F E(m) Dys ?Ca esophagus Growth below upper esophageal sphincter Poorly diff Ca. DD:Small cell ca	61	Siddappa	19210	986/12	54	М	G(pp)	Pain abd	Prepyloric ulcer /?Ca stomach	No significant finding	Ulcer with suppurative necrosis
63 Jayashree 19343 1334/12 44 F D Chr drh Malabsorption No significant findings Chr non-specific duodenitis 64 Chandrakant 19344 1337/12 55 M G(c) Vom,drh Gastritis Gastritis Chr non-specific gastritis 65 Bhagawwa 6746 1431/12 65 F E(m) Dys ?Ca esophagus Growth below upper esophageal sphincter Poorly diff Ca. DD:Small cell ca	62	Gangamma	19328	1290/12	66	F	E(m)	Dys	Ca esophagus	Ulceroproliferative growth	Mod diff SCC
64 Chandrakant 19344 1337/12 55 M G(c) Vom,drh Gastritis Gastritis Chr non-specific gastritis 65 Bhagawwa 6746 1431/12 65 F E(m) Dys ?Ca esophagus Growth below upper esophageal sphincter Poorly diff Ca. DD:Small cell ca	63	Jayashree	19343	1334/12	44	F	D	Chr drh	Malabsorption	No significant findings	Chr non-specific duodenitis
65 Bhagawwa 6746 1431/12 65 F E(m) Dys ?Ca esophagus Growth below upper esophageal sphincter Poorly diff Ca. DD:Small cell ca	64	Chandrakant	19344	1337/12	55	М	G(c)	Vom,drh	Gastritis	Gastritis	Chr non-specific gastritis
	65	Bhagawwa	6746	1431/12	65	F	E(m)	Dys	?Ca esophagus	Growth below upper esophageal sphincter	Poorly diff Ca. DD:Small cell ca

66	Kamanna	19164	16	545/12	65	М	E(1)	Dys	Ca esopahgus Nodular growth Mod diff SCC		Mod diff SCC
67	RajMohammad	19165	16	551/12	71	М	G(f)	Vom	Gastritis No significant finding		Chr non-specific gastritis
68	Iramma	7856	16	586/12	45	F	G(pp)	Pain abd, LOA	Acid peptic disease	Growth in the prepyloric region	Mod diff adenocarcinoma
69	Appasab S	7989	17	12/12	56	М	G(p)	Vom,drh	GOO?malignancy	Pyloric stenosis with ulcer and nodularity	Signet ring adenocarcinoma
70	Iranna	19662	19	063/12	80	М	G(p)	Pain abd,vom	Gastritis	No significant findings	Chr gastritis with intestinal metaplasia
71	Raneeyraja	19456	22	283/12	23	М	D	Chr drh	Malabsortion	No significant findings	Chr non-specific duodenitis
72	Rita Jain	19457	22	284/12	35	F	D	Chr drh	IBD	No significant findings	Chr non-specific duodenitis
73	Bhajantri V	119814	22	290/12	70	М	GEJ	Anx	Barrett's /Ca Esophagus	Nodule in esophagus	Barrett's esophagus
74	Mallanna	19460	22	292/12	49	М	G(p)	Vom	Acid peptic disease	No significant findings	Chr gastritis with intestinal metaplasia
75	Vithal K	19519	23	897/12	21	М	D	Chr drh	Malabsorption	No significant findings	Chr non-specific duodenitis
76	Shranappa	19589	24	97/12	56	М	G(p)	Vom,drh	Ca stomach	Ulceroproliferative growth	Well diff adenocarcinoma
77	Mallikarjun	19584	25	502/12	23	М	D	Ls st	Gastroenteritis	No significant findings	Chr non-specific duodenitis
78	Chandan	19581	25	506/12	60	М	D	Chr drh	Duodenitis	No significant findings	Chr non-specific duodenitis
79	Devappa	147545	25	64/12	38	М	E(u)	Dys	Esophageal carcinoma	Mucosal thickening	Mild dysplasia
80	Vithal M	19743	26	581/12	48	М	D	Ls st	Gastroenteritis	No significant findings	Chr non-specific duodenitis
81	Amruta	19839	29	933/12	33	F	D	Chr drh	Malabsorption	No significant findings	Chr non-specific duodenitis
82	Ramesh Pyuti	168437	29	937/12	48	М	GEJ	Dys	Ca esophagus	Stricture with growth	Mod diff SCC
83	Gangadhar Badiger	13375	29	963/12	65	М	E(m)	Dys COPD	?Ca esophagus	Mid esophageal stricture	Well diff SCC
84	Malliakarjun	19862	30	012/12	36	M	E(m)	Dys	Esophageal Ca	Nodular growth	Chr non-specific esophagitis
85	Shantabai	19873	30	045/12	45	F	E(1)	Vom	Peptic ulcer disease	Ulcer at squamocolumnar junction	Ulcer with foci of granulation
86	Gangadhar	14221	30	085/12	30	M	D	Pain abd	Pain Abd under evaluation	No significant findings	Normal histology
87	Shantabai	178724	31	26/12	45	F	EGAS	Vom,Pain abd	?Recurrent Ca esophageal,? Benign Ulceration	Stricture with growth	Mod diff SCC
88	Shivaraj	19922	31	77/12	15	M	D	Chr drh	Malabsorption	No significant findings	Chr non-specific duodenitis
89	Bhimashri	180992	31	82/12	70	F	E(m)	Dys	Ca esophagus	Growth in esophagus	Well diff SCC
90	Davalat Pujari	14851	32	258/12	70	M	E(m)	Dys	Ca esophagus	Fungating mass	Poor diff SCC
91	Manoj K	19966	33	325/12	48	M	G(pp)	Pain abd	Gastritis	No significant findings	Chr non-specific gastritis
92	Lalsaab	20006	34	12/12	55	M	G(p)	Pain abd, vom	Peptic ulcer disease	Healing ulcer at pylorus	Chr non-specific gastritis
93	Iranna Gouda Dinni	15727	34	195/12	45	М	E(l)	Dys	Severe anemia	Erosions in lower eophagus	Barrett's esophagus
94	Hanmanthray Jumaner	199936	35	500/12	77	M	G(pp)	Pain abd	Gastritis	No significant findings	Chr non-specific gastritis
95	Chohku	20077	35	560/12	60	M	E(m)	Dyp	GERD	Polyp	Hyperplastic polyp
96	Shanawaz	20086	35	579/12	25	M	D	Ls st	Gastroenteritis	No significant findings	Chr non-specific duodenitis
97	Sangamesh	20257	36	512/12	32	M	D	Chr drh	Malabsorption	Loss of mucosal folds	Chr non-specific duodenitis
98	Laxman	16949	37	/99/12	65	M	D	Pain abd	Duodenitis	Duodenal Ulcer with Grade A Esophagitis	Chr non-specific duodenitis
99	Kamalabai	17752	38	\$84/12	84	F	GEJ	Dys	Severe esophagitis/ Barett's esophagus	A small patch of nodularity seen at GEJ	Chr non-specific inflammation
100	Humanappa	19314	41	54/12	80	M	GEJ	Dys	?Ca esophagus	Ulceroproliferative Mass	Well diff adenocarcinoma
101	M S Kumar	243003	42	214/12	39	M	D	Chr drh	Duodenitis	No significant findings	Chr non-specific duodenitis
102	Dnareppa	198441	42	23//12	12	M	E(u)	Dys,Dyp	Ca esophagus	Smooth mable mass	Chr non-specific esophagitis with mild dysplasia
103	Tukkubai	21464	45	028/12	58	F M	E(I)	Dys Dyp	Calesophagus	Ulceroproliferative growth	Well diff SCC
104	Racnappa	278399	48	09/12 62/12	70	E	E(III)	Dys Doin obd	Calesophagus	Dicerated Nodular Friable Growin	Midd dill SCC
105	Parvaubai	20007	40	02/12	60	Г	G(pp)	Pain abd	Castomach	FOIPP	Mod diff adapagarajagama
100	Panut M A Monivor	23007	48	00/12	00	M	G(1)	Pain and	Ca scorbague	Ulceroproliferative growth	Woll diff adenocarcinoma
107	Shiyanna Talikoti	20018	52	002/12	55	M	E(I)	Dys	Europhagitis with pulmonary Kochs	Europionierative glowin	Med diff SCC
100	Savita	V/95/12	52	202/12	20	F	G(n)	Epi ful	Castomach	Illeeroproliferative growth	Poorly diff adenocarcinoma
110	Girish Miraikar	335915	57	132/12	38	M	D	Chr drh	2Sprue	No significant findings	Chr non-specific duodenitis
111	Chandrashekar	21036	58	32/12	44	F	D	Le st	Malabsorption	No significant findings	Chr non-specific duodenitis
112	Ballavantrav H	21030	50	035/12	45	M	D	Ch drh	IBD	No significant findings	Chr non-specific duodenitis
113	Shrishail	21051	60	01/12	40	M	D	Ls st	?\$ппие	No significant findings	Chr non-specific duodenitis
114	Parasuram	21083	2	20/13	42	М	E(1)	Dvs	Ca esophagus	Growth	Mod diff SCC
115	Malasidappa	21235	10	60/13	68	М	E(m)	Dvs	Ca esophagus	Ulceroproliferative growth	Well diff SCC
116	Iranna	21658	5	90/13	32	М	E(m)	Dys	GERD	No significant findings	Chr non-specific esophagitis
117	S B Patil	31266	6	02/13	49	M	E(m)	dys dyp	?Embedded foreign body?Ca esophagus	Nodular swelling	Indequate for opinion
118	GuruNingappa	3900	8	35/13	46	М	G(pp)	Dys	Gastritis	Antral gastritis	H. pylori gastritis
119	Gerngi	21662	92	22/13	76	М	E(1)	Dyp	GERD	Red patch above squamocolumnar junction	Barrett's esophagus
120	Lalu	4902	10)62/13	70	М	E(u)	Dys	?Ca esophagus	Ulceroproliferative growth	Mod diff SCC
121	Sangappa	21531	11	49/13	50	М	G(pp)	Dys	Ca stomach	Ulceroproliferative growth	Poorly diff adenocarcinoma with candidiasis
122	Prakash N	21907	13	888/13	41	М	D	Chr drh	Malabsorption	No significant findings	Chr non-specific duodenitis
123	Siddanagouda Patil	31266	14	71/13	49	М	E(m)	Dys	?Ca esophagus/Benign lesion	Mucosal thickening	Mild dysplasia
124	Girimallu Julapi	6927	14	474/13	65	М	G(f)	Vom,Pain abd	?Ca stomach	Fungating Mass	Mod diff adenocarcinoma
125	Siddaram	8029	16	527/13	60	М	GEJ	Vom,Pain abd	?Ca esophagus	Ulceroproliferative friable growth	Well diff adenocarcinoma
126	Ashok Baraknalli	8261	16	570/13	54	М	E(1)	Dys	?Ca esophagus	Ulcerated nodular growth	Mod diff SCC
127	Parasuram	21083	18	814/13	42	М	E(m)	Dys	Ca esophagus	Ulceroproliferative growth	Mod diff SCC
128	Husanappa	21094	18	817/13	60	М	E(m)	Dys	Ca esophagus	Stricture with growth	Poorly diff Ca
129	Revappa	21125	18	337/13	48	М	E(1)	Dys Dyp	Ca esophagus	Ulceroproliferative growth	Poorly diff Ca. DD: Small cell ca
130	Jairam	5547	11	97/13	80	М	G(pp)	Vom,Pain abd	Acute abdomen	Pre Pyloric Perforation	Candidal infection
131	Annappa	Y/3/13	20	046/13	40	М	D	Chr drh	Malabsorption	Loss of mucosal folds	Chr non-specific duodenitis
132	HussainPasha	22070	20	066/13	87	М	E(m)	Dys	Ca esophagus	Mucosal thickening	Chr non-specific esophagitis
133	Sangappa	10771	21	01/13	60	М	G(pp)	Dys,Dyp	Gastritis	Erosions at prepyloric region	Highly suspicious of malignancy

134	Ambrappa	22084	2168/13	60	М	E(l)	Pain abd	GERD	No significant findings	
135	Sangappa	22219	2288/13	65	М	G(p)	Vom,Pain abd	Gastritis	Polyp at pylorus	
136	Shivappa	12654	2474/13	64	М	D	Chr drh	Malabsorption	No significant findings	
137	Basamma	14090	2711/13	30	F	D	Chr drh	Malabsorption	Loss of mucosal folds	
138	S G Parappannayar	41051	2756/13	75	М	G(pp)	Vom Drh	Gastritis	Ulceroproliferative growth	
139	Sharu	13686	2808/13	52	M	E(m)	Cough	Tracheoesonhageal fistula	Ulceroproliferative growth	
140	Gangubai Balikai	166703	2861/13	68	F	GEI	Pain abd Regur nau	Polyn At GEI	Polyn at GEL	
140	Jrommo	22627	2001/13	75	F	E(1)	Dvc	Calesonhagus	No significant findings	
141	Ammonia	22027	2913/13	13	Г	E(I)	Dys Duo Durr	CEPD	No significant findings	
142	Amrappa	22132	2954/15	00	M	E(I)	Dys,Dyp	GERD	No significant findings	
145	Barawwa Godekar	15604	2948/15	/5	M	E(m)	Dys	Calesophagus	Ulceroproliferative growth	
144	Rajsnekar	16433	3094/13	68	M	E(I)	Dyp		Ulceroproliferative growth	
145	Mayawwa Pujari	16462	3153/13	50	F	D	Chr drh	Periampullary Ca	Ulceroproliferative growth	
146	Nilamma Hiremath	184226	3159/13	55	F	G(pp)	Vom,Drh	Pan gastritis	Pangastritis	
147	Shivanna	17173	3238/13	61	M	D	Cp,Brt	Severe anemia	No significant findings	
148	Shakrappa Nidoni	194833	3302/13	75	M	E(l)	Dys	?Ca esophagus	Ulceroproliferative growth	
149	Neelamma	192391	3326/13	50	F	E(m)	Dyp	GERD	No significant findings	
150	Chandappa	209565	3561/13	50	Μ	E(m)	Dys	Ca esophagus	Ulcerated nodular friable growth	
151	Rajshekar Mannur	21016	3877/13	70	М	GEJ	Dys,vom	?Benign stricture?Ca esophagus	Strictures with growth	
152	Vishnu Madar	247200	4128/13	30	М	G(pp)	Dys	Healing ulcers in prepyloric region	Ulcers at prepyloric region	
153	Kashinath	23726	4245/13	30	М	E(1)	Dyp	Esopahgitis	No significant findings	
154	Loku	20733	4475/13	40	М	G(p)	Dys	Ca stomach	Ulcerated nodular friable growth	
155	Ramu Rathod	24932	4496/13	40	М	GEJ	Vom,Pain abd	?Ca esophagus	Ulceroproliferative growth	
156	Shankarppa	26396	4728/13	66	М	E(1)	Dys	Ca esophagus	Stricture	
157	Kallawwa M	26613	4758/13	80	F	G(c)	Pain abd, vom	Upper GI obstruction	Growth in Lesser Curvature	
158	H B Desai	292123	4798/13	72	М	G(pp)	Pain abd	Pangastritis	Pangastritis	
159	Hemareddy Biradar	28154	5014/13	55	M	G(p)	Pain abd yom	GOO?malignancy	Ulceroproliferative growth	
160	Manohar	23/15	5237/13	32	M	D D	Chr drh	B/o Sprue	No significant findings	
161	Rechenne	23415	5402/12	20	M	D	Chr drh	Melekoemtion	No significant findings	
162	Ironno	23890	5424/12	24	M	D	Leat	P/o Spruo	Loss of mucocal folds	
162	Italilla	23912	5506/12	24	M	D C(r)	LS St Vom deb	Costritio	Eoss of indeosal folds	
165	Isarali	20678	5506/15	24	M	G(p)	vom,drn	Gastritis	Erosions at pyloric region	
164	Siddaramappa	20667	5516/15	45	M		Chr drh	Sprue	Loss of mucosal folds	
165	Motiram Rathod	20737	5623/13	55	M	E(m)	Dys	ca esophagus	No significant findings	
166	Sharanappa	519	5/45/13	51	M	GEJ	Dys	?Malignancy	Growth at GEJ	
167	Ashok	20815	5777/13	53	M	E(I)	Dys	Ca esophagus	Ulceroproliferative growth	
168	B H Pujari	20952	5848/13	63	M	E(1)	Dys	Ca esophagus	Ulcerated growth	
169	Kaldappa	20842	5852/13	65	M	E(m)	Dyp	Ca esophagus	Stricture	
170	Gurubasappa	20874	5859/13	74	M	E(l)	Dys,Dyp	Ca esophagus	Ulceroproliferative growth	
171	Baburao	20872	5860/13	80	М	G(pp)	Dys,vom	Ca stomach	Ulceroproliferative growth	
172	Hanamawwa	20857	5865/13	50	F	G(p)	Dys,vom	Ca stomach	Large ulcer at pylorus	
173	Sevalal	20940	5866/13	50	Μ	E(1)	Dyp	Ca esophagus	Stricture with growth	
174	Shobha	2398	5942/13	40	F	G(p)	Vom, Pain abd	Ca Stomach	Nodules in pylorus	
175	Mallapaa	22533	6014/13	62	Μ	G(pp)	Vom,dys	Ca stomach	Ulceroproliferative growth	
176	Chanappa	22421	6081/13	73	М	E(1)	Dys	?Ca esophagus	Ulceroproliferative growth	
177	Kamala	24137	6318/13	65	F	E(m)	Dys, Dyp	Ca esophagus	Ulcerated nodular growth	
178	Ramesh	24135	6319/13	30	М	D	Ls st	Malabsortion	No significant findings	
179	Suresh	24042	6510/13	42	М	D	Chr drh	?Sprue	Loss of mucosal folds	
180	Parvati	23981	6728/13	30	F	D	Chr drh	Malabsorption	loss of mucosal folds	
181	Nirmala	23969	6738/13	42	F	D	Ls st	R/o Sprue	No significant findings	
182	Siddu	23963	42/14	30	М	D	Ls st	R/o Sprue	No significant findings	Vi
183	Shiyappa	22712	129/14	63	M	D	Pain abd	Gastritis	No significant findings	
184	Hanumant	22757	246/14	30	M	D	Chr. drh	R/o Sprile	No significant findings	
185	Mallanna	24244	256/14	30	M	D	Lest	P/o Sprue	No significant findings	
105	Lingayot	24244	512/14	10	M		Lost	D/o Spruc	Loss of muccoal folds	-
100	Ci dalin commo	50255	1206/14	19	E	E(I)	LS SI	K/o Sprue	Loss of indeosal folds	
18/	Short: Data	39255	1390/14	08	r V	E(I)	Dys Dr. D	Calesophagus	Nodular Swelling	
188	Snanta Babanagar	65090	14/0/14	58	M	E(I)	Dys,Dyp	Ca esophagus	Stricture with growth	
189	Mahadev	/6419	1684/14	50	M	G(p)	Dys	Ca stomach	Ulceroproliterative growth	
190	Shikarappa	7841	1900/14	47	M	E(u)	Dyp	Ca esophagus	Strictures with growth	
191	Shakuntala	108065	2196/14	50	F	E(m)	Dys	Ca esophagus	Stricture with growth	
192	Siddawwa	126341	2471/14	65	F	E(1)	Dys	Ca esophagus	Ulceroproliferative growth	
193	Neelakantaiyya	127039	2494/14	70	М	E(u)	Dys	Ca esophagus	Circumferential ulceroproliferative growth	
194	Mrs Saleem D	24552	2507/14	52	F	G(pp)	Vom,Dyp	Gastritis	Erosions at prepyloric region	
195	Gouramma	210041	3747/14	65	F	GEJ	Dys	Ca esophagus	Strictures with growth	
196	Kamala	213824	3811/14	65	F	E(m)	Dys	Ca esophagus	Growth	

Chr non-specific esophagitis
Adenomatous polyp
Chr non-specific duodenitis
Chr non-specific duodenitis
Poorly diff Ca
Mod diff SCC
Hyperplastic polyp
Chr non-specific esophagitis
Chr non-specific esophagitis
Mod diff SCC
Mod diff SCC
Well diff adenocrcinoma
Chr non-specific gastritis
Chr non-specific duodenitis
Mod diff adenocarcinoma
Chr non-specific esophagitis
Mod diff SCC
Well diff adenocarcinoma
Chr non-specific gastritis
Chr non-specific esophagitis
Mod diff adenocarcinoma
Mod diff adenocarcinoma
Mod diff SCC
Signet ring adenocarcinoma
Chr non-specific gastritis
Well diff adenocarcinoma
Chr non-specific duodenitis
Chr non-specific duodenitis
Chr non-specific duodenitis
Well diff adenocarcinoma
Chr non-specific duodenitis
Chr non-specific esophagitis
Mod diff adenocarcinoma
Well diff SCC
Mod diff SCC
Mod diff SCC
Mod diff SCC
Well diff adenocarcinoma
Poor diff adenocarcinoma
Well diff SCC
Chr non-specific gastritis
Poorly diff ca
Inadequate for opinion
Poorly diff SCC
Chr non-specific duodenitis
/illous atrophy with crypt hyperplasia
Chr non-specific duodenitis
Ciliated metaplasia
Well diff SCC with candidiasis
Mod diff adenocarcinoma
Indequate for opinion
Poorly diff SCC
Mod diff SCC
Indequate for opinion
Chr non-specific gastritis
Mod diff SCC
Well diff SCC